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CD8+ T lymphocytes are an important component of adaptive immunity, 
capable of specific identification of a foreign antigen, rapid proliferation, and 
cytotoxic activity to kill cells expressing the targeted antigen. T cell activation 
occurs via engagement of the T cell receptor (TCR) by its cognate antigen within 
the context of the MHC molecule and is modulated by co-receptors that function 
to either support or inhibit activation. The adaptive immune system, and T cells in 
particular, are important for their ability to recognize and eliminate nascent 
tumors in cancer immunosurveillance and tumor rejection. However multiple 
inhibitory mechanisms within the tumor microenvironment have been described 
that protect the tumor from T cells, including increased signaling of inhibitory co-
receptors. Lysophosphatidic acid (LPA) is a lysophospholipid that is present at 
low nanomolar concentrations in the plasma of healthy individuals. It has been 
well documented that many cancers aberrantly produce LPA and the increased 
level of LPA has been shown to be beneficial to the tumor, promoting 
tumorigenesis, invasion, metastases, and vascularization. However the effects of 
elevated levels of LPA on the adaptive immune response have not been 
addressed. We demonstrate here that LPA inhibits CD8+ T cell activation in vitro 
and in vivo. Specifically, we show that CD8+ T cells express LPA receptor 5 
iv 
 
(LPA5) that, in the presence of LPA, is able to inhibit TCR signaling and 
subsequent cell activation and proliferation. These data document that LPA is 
able to negatively regulate T cell activation and that LPA5 functions as an 
inhibitory T cell co-receptor. Finally, we have shown that transfer of LPA5-
deficient T cells is able to abate tumor progression. We propose that 
lysophospholipid signaling is an additional protective mechanism of the tumor 
microenvironment to avoid anti-tumor CD8+ T cell immunity. 
 
The form and content of this abstract are approved. I recommend its 
publication. 
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INTRODUCTION AND BACKGROUND 
 
 
The adaptive immune response 
 The adaptive immune system is composed of specialized cells including B 
and T lymphocytes. In contrast to the innate immune system which targets 
foreign invaders by recognition of components shared by many pathogens, the 
adaptive immune response is capable of specifically identifying and responding 
to a particular epitope of a pathogen, contributing to pathogen clearance, and 
subsequently generating a population of memory cells that will mount a stronger 
attack in the event of a future repeat assault. CD8+ T cells are a subset of T cells 
that are capable of tremendous expansion and differentiation to effector cells that 
clear infection throughout the body via cytotoxic activity (1). 
 The importance of CD8+ T cells was demonstrated (though not fully 
understood) at the beginning of the last century, when James Murphy 
experimented with rat tumor cell implantation into chick embryos (2). Although 
the tumor cells “would not take” in older chicks, tumor cells would successfully 
grow in chick embryos until the chicks aged (3) and as we now know, developed 
an immune system (2). Resistance to the tumor could be restored by graft of 
adult lymphoid tissue near the tumor transplant (4). Although B cells had already 
been identified, CD8+ T cells would be later discovered to be a distinct cell type 
by their origin (thymus-derived) and cytotoxic abilities (2).   
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 The T cell receptor (TCR) was eventually characterized and revealed that 
T cells require foreign antigen to be presented by an antigen presenting cell 
(APC) in the context of an endogenous protein, the major histocompatibility 
complex (MHC) (5-9). T cell activation is initiated when the T cell receptor (TCR) 
is engaged by the MHC-peptide complex (10, 11). This activation can be 
bolstered by co-stimulation by cell surface molecules on the APC that engage the 
appropriate receptor on the T cell, such as the B7 molecule of the APC binding to 
CD28 on the T cell (12). Although it was once believed that CD28 signaling was 
required for T cell activation, it is now known that strong TCR engagement can 
negate the need for co-stimulation (13). ICOS and 4-1BB are other T cell co-
stimulatory receptors that function to enhance the T cell response (14-16). 
 At the other end of the spectrum, co-receptors can also function to 
dampen T cell activation, such as the receptors CTLA-4, PD-1, and TIM-3 (13-15, 
17-19). CTLA-4 is expressed at low levels on resting T cells and is upregulated 
upon activation (13). The ligands for both the inhibitory CTLA-4 and stimulatory 
CD28 T cell co-receptors are B7 molecules on APC, however CTLA-4 has a 
higher affinity for B7 and thus outcompetes CD28 to result in preference to 
inhibition over costimulation (14). 
The importance of inhibitory “brakes” for the T cell response is evidenced 
in the impressive magnitude of response of which T cells are capable. In 
response to infection, the naïve CD8+ T cells can yield up to 15 rounds of division, 
generating more than 10,000 daughter cells within a week (20). In addition, it is 
becoming increasingly appreciated that T cells must exert a degree of 
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promiscuity, as Bob Mason notably calculated that if T cells were monospecific, 
the volume of the lymphoid system required to include every naïve CD4+ T cell 
for each possible MHC-associated peptide (1015 CD4+ T cells) would be over 70 
times larger than the volume of a mouse (21, 22). Thus he concluded that the 
TCR repertoire must be substantially smaller and necessarily cross-reactive to 
generate effective immunity (22), and recent studies have estimated that fewer 
than 108 distinct TCRs exist in the human naïve T cell repertoire (21). The 
activation of cross-reactive T cells is not equivalent for all peptides and activation 
of T cells by lower affinity antigens typically results in reduced CD8+ T cell 
activation and expansion (23, 24). This modulation of response is now being 
more carefully analyzed, with studies interrogating the differences between 
peptide affinity and co-stimulation, and resultant clearance of infection, 
differentiation, and memory response (23-28).  
It is because of this ability to generate a powerful response that the 
activation of these cross-reactive CD8+ T cells must be carefully regulated. 
Inappropriate activation of CD8+ T cells has been associated with various 
autoimmune diseases, including type I diabetes and multiple sclerosis (29). 
However, the potency of CD8+ T cell immunity is increasingly being explored for 
therapeutic strategies to combat infections and cancer, and studies are ongoing 
to enhance the CD8+ T cell response by modulating signaling of inhibitory and 




CD8+ T cells and cancer 
Cancer immunotherapy is an expanding field of research that can 
potentially offer a targeted, effective approach by harnessing the patient’s 
immune system to reject the tumor. Attempts to stimulate antitumor immunity 
were first performed by surgeon William Coley in 1891 by injecting bacteria into 
the sarcoma tumors of patients. Although he experienced variable success in 
inducing cancer remission, ‘Coley’s toxins’ may have promoted antitumoral 
immunity by activating phagocytes to kill bystander tumor cells (32).  
Analyses of genetically manipulated mouse strains have demonstrated 
that the immune system is important to recognize and eradicate tumor cells (33-
35). CD8+ T cells can specifically identify and eliminate tumor cells expressing 
tumor antigens recognized by their TCRs, in a process termed “cancer 
immunosurveillance” (33). The presence of tumor-infiltrating T cells is a positive 
prognostic factor for various cancers including melanoma, breast, and ovarian 
cancers (36, 37) and a high proportion of intratumoral CD8+ T cells (of total T 
cells) favors tumor rejection in both human and mouse (37). 
Although tumor masses can support activation and differentiation of naïve 
T cells (38), multiple inhibitory mechanisms within the tumor microenvironment 
have been described that impede tumor rejection by T cells (39-42). These 
mechanisms range from induced apoptosis via tumoral FasL expression (42, 43) 
to increased signaling of T cell inhibitory receptors (19), such as the well 
characterized CTLA-4 molecule (31). An additional obstacle is that high affinity 
tumor-specific T cells have been reported to be deleted during thymic education, 
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therefore T cells specific for tumor antigens typically display low affinity for these 
‘self tumor antigens’ (44-47), resulting in reduced CD8+ T cell activation and 
expansion (23, 24).  
Various therapies are being explored to enhance the T cell response to 
tumor. One such therapy is to isolate T cells from the patient, stimulate T cells 
with tumor antigen outside of the immunosuppressive tumor environment, then 
transfer T cells back into the patient (48). A similar therapy is to determine which 
cancer associated antigens will stimulate anti-tumor T cells and then immunize 
patients with those antigens or modified, more immunogenic antigens to induce a 
specific T cell response (49-51). Other studies have focused on enhancing the 
function of the APC, such as enhancing dendritic cell activation and antigen 
presentation, as an indirect route to enhance the T cell response (52, 53). 
Importantly, drugs and combinations of drugs to block inhibitory signaling and 
enhance costimulation are being tested in labs and the clinic (54-56). Of note, 
blocking CTLA-4 signaling by monoclonal antibody therapy (Yervoy) was 
approved by the FDA in 2011 and has made significant progress in treating 
metastatic melanoma patients when conventional therapies have failed (32, 37). 
The success of these therapies illustrates the importance of targeting CD8+ T 
cells to eradicate cancer cells. 
 
Lysophosphatidic acid 
 Lysophosphatidic acid (LPA) is a phospholipid that is present in all 
eukaryotic tissues at low concentrations and at higher concentrations in the blood 
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(57). LPA is related to another phospholipid, sphingosine-1-phosphate (S1P), 
which is best known in the immunology field for its role in directing lymphocyte 
migration and retention in lymphoid organs (58). The influence of LPA on cell 




LPA is a structurally simple molecule, consisting of a phosphate head 
group, glycerol backbone, and acyl chain. Different molecular species of LPA 
exist and each LPA receptor has a distinct ligand preference for LPA species 
(59). Sources of variation exist in the position of esterification of the fatty acid to 
the glycerol backbone (sn-1 or sn-2), the type of chemical linkage to the glycerol 
backbone (alkyl or alkenyl-ether), and the degree of saturation or unsaturation of 
the aliphatic chain (Figure 1.1)(60). For our purposes, we will refer to LPA 
molecular species by the length and degree of unsaturation of the carbon chain 
(i.e. 16:0 indicates a 16-carbon chain with no degree of unsaturation) and the 
type of linkage (ether versus ester). LPA is challenging to work with: it easily 
adheres to plastic surfaces and is notoriously difficult to extract and quantify from 
tissue and blood, resulting in variable reported concentrations of LPA within 
tissues and serum (61, 62). However it appears that a consensus of the most 
common species in human plasma include 18:2, 16:0, 18:1, and 20:4, though the 
relative abundance of these 4 species is still debated (57, 63-65). The 18:1 
molecular species is most commonly used in studies (57). 
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LPA is readily degraded both in vitro and in vivo with a reported half-life as 
rapid as 3 minutes in the blood after intravenous injection of radiolabeled LPA 
(66). Therefore, various metabolically stable LPA analogs have been synthesized 
to modulate LPA signaling (63, 67). One of these analogs, octadecenyl 
thiophosphate (OTP) is an 18:1 LPA analog that has been reported to have a 





Figure 1.1 Chemical structures of LPA 
Moieties of LPA can differ in the length of carbon chain and degree of 
unsaturation (e.g. 18:1 is an aliphatic substituent with an 18-carbon chain 
with 1 degree of unsaturation). Species of LPA can also differ in the 
linkage to the glycerol backbone; by either an ester or ether linkage (ether-
LPAs are also known as alkyl glycerophosphate, AGP). OTP is a 
metabolically stable LPA analog that lacks the glycerol backbone and has 
a sulfur substitution for an oxygen within the phosphate headgroup. Figure 









LPA is primarily generated in vivo via an extracellular lysophospholipase D, 
autotaxin (ATX), which converts lysophosphatidylcholine (LPC) to LPA (Figure 
1.2A). ATX was originally isolated from a melanoma cell line and identified as a 
cancer cell motility stimulating factor (70). ATX-null mice die before birth however 
ATX+/– mice feature half of the plasma concentration of LPA of normal mice (71, 
72), indicating that production by ATX is likely the major source of plasma LPA. 
This discovery has led researchers to develop ATX inhibitors as a method of 
reducing LPA concentrations in vivo (73-75). Another method of LPA generation 
is the conversion of intracellular phosphatidic acid (PA) to LPA by the enzymes, 
phospholipase A1 and phospholipase A2 (PLA1, PLA2) (Figure 1.2A) (57, 76). 
This mechanism has been shown to be important for LPA production by activated 
platelets during blood coagulation (77, 78).  
Extracellular LPA levels in healthy individuals is a balance of synthesis by 
ATX from the abundantly available precursor molecule, LPC, which is secreted 
by the liver (>200 µM in plasma)(79, 80) and subsequent degradation of LPA 
(Figure 1.2A)(81-83). Physiological levels of LPA are tightly regulated with 
concentrations in plasma reported in the hundred nanomolar range (63). LPA is 
degraded in vivo by lipid phosphate phosphatases (LPP1-3), which inactivate 
LPA by conversion to monoacylglycerol (MAG, Figure 1.2A). In particular, LPP1 
has been shown to be important for LPA degradation as LPP1–/– mice 
metabolize injected LPA 4 times slower than wild-type (66). Significantly elevated 
  9 
LPA levels, up to 10 µM, are observed in individuals with certain tumors and 
other pathophysiological conditions (84-90).  
The structure of autotaxin was solved in 2011 by two independent groups 
with complementary results (91, 92). Mutational analysis has shown that ATX 
binds to cells via the SMB2 domain to β3 integrins on the surface of mammalian 
cells, thus directly releasing LPA to surface LPA receptors and efficiently 
initiating LPA signaling to that cell (Figure 1.2B) (91-94). The strength of LPA 






Figure 1.2 LPA metabolism 
(A) LPA is generated primarily in vivo by the actions of ATX from the 
precursor molecule LPC. LPA can also be generated from PA by PLA1 
and PLA2. LPA is degraded by LPP to MAG. 
(B) ATX binds to cells via integrins and releases LPA to surface receptors. 
Figure 1.2A adapted from Moolenaar et al, 2004 (95). Figure 1.2B adapted 












Although LPA was previously better known as a lipid metabolism 
intermediate (63), it is now appreciated for a variety of effects on cell function by 
binding to extracellular receptors and induction of intracellular signaling pathways. 
There are currently 6 confirmed LPA receptors that signal by coupling to and 
activating G proteins (GPCR)(57) and these receptors are annotated LPA1-6 (96). 
Although the first three receptors were discovered in quick succession (LPA1, 
1996 (97); LPA2, 1998 (97, 98); LPA3, 1999 (99)), LPA4-6 were discovered up to 
10 years later and other proposed LPA receptors are still awaiting validation (57, 
96). LPA4-6 were de-orphaned later than LPA1-3 as they were discovered to 
belong to a different branch of the GPCR family (76), revealing convergent 
evolution of these two families of receptors. Phylogenetic analysis reveals that 
while LPA1-3 share 50-57% amino acid sequence and LPA4-6 share 35-55% 
homology, the LPA homology between phylogenetic groups is low (Figure 
1.3)(76). LPA1-3 share homology with classical S1P receptors (S1P1-5) whereas 
LPA4-6 share similarities with purinergic receptors (57, 60), allowing diverse 
functions. In addition, different LPA receptors preferentially couple to specific G 
proteins and the combination of LPA receptor with a given G protein increases 





Figure 1.3 LPA receptor homology 
A phylogenetic tree for selected human GPCR. LPA receptors are circled 
in red and S1P receptors are circled in blue. LPA1-3 share homology with 
S1P receptors and other Edg family receptors while LPA4-6 are more 
closely aligned with the purinergic receptors. Figure adapted from Ishii et 
al, 2009 (76). 
 
 
 In addition to these extracellular receptors, an intracellular receptor, 
PPARγ, has been described that is stimulated by unsaturated LPA molecular 
species (100-102). Extracellular LPA had no effect on PPARγ signaling (101) and 
PPARγ–/– mice have been shown to have defective arterial wall remodeling, 





LPA has been reported to induce a variety of sometimes opposing 
activities in different cell types, including proliferation, protection from apoptosis, 
cell death, migration, adhesion, and activation (63, 79, 104, 105). Although it is 
perplexing that a structurally simple molecule can have such a varied impact, this 
heterogeneity is mediated by the diversity of LPA receptors coupled with the 
different G protein signaling pathways (106). Edg family receptors (LPA1-3) have 
been reported to induce Ca2+ mobilization, mediate protein-kinase activation, 
inhibit adenylyl cyclase, and prefer acyl-LPA to alkyl-LPA (60). As the non-Edg 
family LPA receptors (LPA4-6) were discovered more recently, these signaling 
pathways are not yet fully characterized (59). There have been reports of 
associations of LPA4 with vascular development and bone formation, whereas 
LPA6 has been found to have an effect on hair growth (59). 
 
LPA receptor 5 
 GPR92 was deorphaned and identified as LPA5 in 2006 (107, 108), with 
acceptance by the International Union of Basic and Clinical Pharmacology 
(IUPHAR) in 2010 (96). LPA5 has been shown to induce Ca2+ mobilization when 
coupled to Gαq and induce neurite retraction when coupled to Gα12/13 (108).  
Reports have also identified non-LPA ligands for LPA5, including farnesyl 
pyrophosphate (FPP) and N-arachidonoylglycine (NAG) (109). However, others 
have confirmed the identity of GPR92 as an LPA receptor by determination that 
the concentration required to activate LPA5 for non-LPA ligands is much greater 
than LPA (110, 111). Thus, the physiological relevance of non-LPA ligands as 
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activators of LPA5 remains to be shown (57). The LPA ligand preference for LPA5 
is ether-linked (also known as alkyl glycerol phosphate; AGP) over ester-linked 
molecular species (110). 
The Lpar5 gene spans 2 exons; the first exon is non-coding, thus the 
coding sequence is contained within exon 2 (108). In mice, Lpar5 is located on 
chromosome 6 and in humans, on chromosome 12 (LPAR5) (57). Lpar5 is 
expressed in various tissues, including the heart, small intestine, liver, and has 
moderate to high expression in the spleen of both mice and humans (57).  
As LPA5 was discovered recently in 2006 (107, 108), the research 
regarding the effects of LPA5 signaling is limited. LPA5 has received considerable 
attention for its role in platelet activation and it has been suggested that inhibition 
of LPA5 signaling may be a promising anti-thrombotic therapy (110, 112, 113). 
Signaling via LPA5 was shown to cause release of the inflammatory protein, MIP-
1β, by mast cells (114). Intestinal CD8+ T cells were found to have high 
expression of LPA5, though the role of LPA5 signaling in these cells was not 
elucidated (107). Recently, a group generated an LPA5-deficient mouse and 
discovered that these mice were protected from neuropathic pain (115). 
 
LPA and cancer 
LPA has a strong association with cancer where it is not only aberrantly 
expressed by a number of different malignant cell types (84-87), but has also has 
been shown to enhance tumor progression (116-118). Various tumors have been 
shown to produce aberrant levels of LPA and ascites concentrations up to 10 µM 
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have been reported in patients with certain tumors, including ovarian, cervical, 
and myeloma cancers (84-87, 90). High expression of ATX has also been 
associated with a variety of tumor cell types, including thyroid carcinoma, breast 
cancer, neuroblastoma, renal cell carcinoma, hepatocellular carcinoma, 
glioblastoma, and non-small cell lung cancer (NSCLC) (63, 116).  
The elevated level of LPA has been shown to stimulate migration, survival, 
metastases, angiogenesis, drug resistance, and proliferation of cancer cells (119-
125). Increased LPA signaling can directly promote tumorigenesis, as it has been 
demonstrated that overexpression of ATX or LPA1-3 under an MMTV-LTR 
promoter was sufficient to induce mammary carcinomas (126).  Ovarian cancer 
cells have been shown to upregulate LPA2, thus upregulating LPA signaling 
resulting in cell survival, proliferation, angiogenesis, increased migration, and 
tissue invasion (57).  The dramatic increase in LPA2 also resulted in a lowered 
threshold of signaling, to low nanomolar concentrations of LPA. In a separate 
study, enforced expression of LPA3 increased chemotherapy drug resistance 
(cisplatin and doxorubicin) in a mouse mammary tumor (127). 
LPA signaling has also been implicated in migration and metastasis of 
cancer cells. LPA has been shown to stimulate migration in ovarian, prostate, 
pancreatic, and breast cancer cells (121, 123, 128, 129). Interestingly, one group 
found that B16 melanoma metastases were reduced in LPA5-deficient hosts, 
indicating that LPA5 on endogenous tissues facilitates migration of cancer cells 
(Gabor Tigyi, unpublished data). Another group recently reported that LPA acts 
as a chemorepellent for B16 melanoma cells and that silencing of LPA5 on the 
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cancer cells ablated this effect (130). This could suggest that LPA signaling via 
LPA5 causes migration from the original tumor site, where LPA levels are the 
highest, thus promoting metastasis. 
 
LPA and immune cells 
The reported effects of LPA signaling on different immune cell types are 
diverse. As before mentioned, LPA signaling via LPA5 has been reported to be 
responsible for mast cell release of MIP-1β (CCL4), an inflammatory protein that 
is a chemoattractant for monocytes, lymphocytes, and other immune cells (114). 
In contrast, LPA has been reported to inhibit the cytotoxic activity of NK cells via 
LPA2 (131). In the human monocytic line, THP-1, LPA induced migration in a 
pertussis toxin-sensitive manner (132). Intriguingly, the effect of LPA on dendritic 
cells (DC) has been found to be dependent on maturation status. In immature DC, 
LPA induced chemotaxis however this effect was not observed in mature DC 
(133, 134). LPA has also been reported to impact DC by regulating expression 
and function of CD1 antigen-presenting molecules (135) and inhibiting activation 
(136). As a major antigen presenting cell (APC), modulation of DC function would 
likely also affect the T cell response. 
It has been previously demonstrated that a lysophospholipid can influence 
adaptive immunity through studies of S1P, which is structurally similar to LPA 
and plays an important role in directing lymphocyte trafficking, localization and 
development (137-142). Studies from the past 20 years documenting the effects 
of LPA signaling on T cells are limited, sometimes contradictory, and have 
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focused on human primary CD4+ cells and T cell lines (57).  LPA has been 
reported to induce calcium mobilization in cytokine-induced human Th1 and Th2 
cells (143, 144) whereas in contrast, a separate study reported that LPA does not 
regulate calcium entry into human Jurkat T cells (145). LPA has been reported to 
have an inhibitory effect on IL-2 production of CD4+ cells (146) but promotes IL-
13 production (a cytokine important for asthma pathogenesis) (147). Interestingly, 
isolated CD4+ T cells from two human donors produced increased amounts of IL-
13 with LPA treatment with submaximal anti-CD3 stimulation (0.5 µg/mL) but not 
higher concentrations (1-10 µg/mL). Notably, LPA treatment did not affect IL-4 
nor IFNγ production in this study. 
The variability in reports of the effect of LPA signaling on T cell activation 
reveal that more work needs to be done as the LPA receptor(s) involved, precise 
mechanism and effects are not congruently elucidated (148).  As LPA is readily 
degraded in vivo and in culture, some of the variability in reports could be 
attributed to this property.  Sevastou et al. recently published a review that 
meticulously summarizes previous work and notes LPA concentration and culture 
conditions, further emphasizing the variability and difficulty of in vitro LPA 
experiments (2012).  
 Recently, others have investigated the effect of LPA signaling on T cell 
migration, given the finding that S1P has been shown to be important for 
lymphocyte trafficking (139, 141). As ATX is tethered to cells by integrin 
receptors (91, 93, 149, 150), the resultant increased LPA concentration has been 
shown to induce chemokinesis or chemorepulsion in T cells (132, 149, 151). This 
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coincides with data from our lab that LPA causes a small but significant degree of 
chemorepulsion but not chemotaxis in B cells (Figure 1.4). Injection of 
enzymatically inactive ATX slightly decreased homing of T cells to lymph nodes, 
which the authors attributed to displacement of functional endogenous ATX 
resulting in attenuated chemokinesis and subsequent diapedesis (149). In this 
study, expression of chemokine receptors CXCR4 and CCR7 were not affected 
by LPA treatment in vitro and the LPA receptor(s) responsible for this phenotype 
was not identified. 
 
 
Figure 1.4 LPA induces chemorepulsion in splenic B cells 
Transwell migration assay (5 µm pore size) of erythrocyte-lysed C57BL/6 
splenocytes added to the upper chamber with 1 µM LPA added either to 
the same chamber (to induce chemokinesis/chemorepulsion), to the lower 
chamber (to induce chemotaxis) or to both chambers (blue bars, n=3, 
*p<0.05). After a 3h incubation at 37°C, B cells that had migrated to the 
bottom chamber were quantified by flow cytometry (B220+). Right, 
CXCL12 (50 ng/ml) serves as a lymphocyte chemoattractant positive 
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 In comparison with T cells, far fewer studies have been done to examine 
how LPA affects the B cell response. In our lab, we have found that LPA 
functions to dampen antigen receptor signaling in another adaptive immune cell, 
B cells. We have found that LPA inhibits B cell antigen receptor signaling via 
LPA5 and that this inhibition leads to decreased activation and antibody 
production (152).  
 
Summary 
  The adaptive immune response and CD8+ T cells in particular are 
tremendously important not only to protect the host from pathogens but also to 
combat endogenous threats, such as cancer. Lysophosphatidic acid is a 
pleiotropic molecule that elicits a variety of responses in different cell types and 
has been shown to be released at increased concentrations as a result of various 
tumors, however the effect of LPA signaling on antigen receptor signaling of 
CD8+ T cells remains to be addressed. We have found previously in B cells that 
LPA functions to inhibit antigen receptor signaling, activation, effector function, 
and induces chemorepulsion (unpublished observations). Given the signaling 
similarities between B and T cells, we questioned if this inhibition of antigen 
receptor signaling also occurred with T cells. We hypothesized that increased 
LPA signaling will similarly dampen the CD8+ T cell response and questioned if 
this inhibition could be an additional inhibitory mechanism featured in the tumor 
microenvironment. The work presented here shows that LPA signaling inhibits 
CD8+ T cell activation and proliferation via LPA5 and that LPA more potently 
inhibits activation to a lower affinity peptide. In addition, we show that ablation of 
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LPA5 signaling on tumor-specific CD8+ T cells allows better control of tumor 
progression and suggest that this may represent a new therapeutic target to 













Specific pathogen-free, C57BL/6 (CD45.2) and CD45.1 (B6.SJL-Ptprca 
Pepcb/BoyJ) were obtained from Jackson Laboratories or bred in the Biological 
Resource Center (BRC) at National Jewish Health (NJH). CD45.1 OT-I mice 
(153)(gift of Dr. Ross Kedl, University of Colorado), LPA2–/– mice (154)(gift of Dr. 
Jerold Chun, Scripps Research Institute), LPA5–/– mice (gift of Lexicon 
Pharmaceuticals), and TCRα–/– mice (gift of Dr. Philippa Marrack, National 
Jewish Health) were bred in the BRC at NJH. All mice used were 8-12 weeks of 
age and were maintained and treated in accordance with the regulations of the 
Institutional Animal Care and Use Committee.  
OT-I and CD45.1 mice were typed by flow cytometry. Briefly, peripheral 
blood was collected and lysed by water, then neutralized with 10X HBSS. The 
remaining cells were pelleted and stained as described below. OT-I mice were 
considered >90% Vα2+Vβ5+ and >90% CD8+ of Thy1.2+. 
 LPA5–/– mice were generated by targeted replacement of exon 1 with a 
LacZ/neo cassette (Figure 2.1A). Deletion was confirmed by PCR and southern 
blots at Lexicon Pharmaceuticals (Figure 2.B,C). Heterozygous crosses resulted 
in Mendelian ratios of pups with no obvious phenotypic differences (Figure 2.1D 
and data not shown). LPA5–/– mice were generated on a mixed 129/SvEvBrd and 
  21 
C57BL/6J genetic background and were continually backcrossed with C57BL/6 
mice. LPA5–/– mice were backcrossed 2-6 generations before analysis together 
with gender-matched LPA5+/+ littermates as controls. LPA5 mice were genotyped 
by PCR with the following primers (Fig 2.1):  
Neo-sense   GCAGCGCATCGCCTTCTATC,  
9-sense   CCAACTGCGTGCTGGATC, 




Figure 2.1 Generation of LPA5–/– mice 
(A) Schematic diagram of Lpar5 targeted deletion. A portion of the Lpar5 
gene was replaced with a LacZ/neo selection cassette. 
(B) PCR genotyping displaying wild-type and mutant Lpar5. Primers are 
indicated in (A) as “9”, “22”, and “neo”. 
(C) Southern hybridization indicating the proper targeting event in ESC 
clones. Restriction sites and probe locations are indicated in (A). 
(D) The proportion of pups that were LPA5–/– (KO), LPA5+/– (Het), or 




































































Mouse cells were erythrocyte-lysed with ACK lysis buffer and splenocytes, 
pooled lymph node cells, or purified CD8+ T cells were suspended at 20 x 106 
cells/mL in RPMI 1640 medium (Fisher Scientific) supplemented with 2.5% fatty-
acid free (faf) BSA (Calbiochem), to minimize background levels of extracellular 
LPA. Indo1-AM was added to a final concentration of 5 µM and incubated for 30 
minutes at 37°C. Antibodies for extracellular staining were added for the final 20 
minutes. Cells were washed and resuspended at 4-6 x 106 cells/mL before 
analysis on the LSRII. For data acquisition, a baseline reading was measured for 
30 sec, then the sample was removed from the instrument and LPA or vehicle 
control was added immediately and AgR stimulation (for B cells, 20 µg/mL anti-
IgM F(ab’)2 [goat anti-mouse, Jackson ImmunoResearch Laboratories]; for T 
cells, 10 µg/mL anti-CD3e biotin pretreatment [145-2c11, BD Biosciences], 
ligated by 20 µg/mL avidin [Invitrogen]) was added at 39 sec (155). The sample 
was returned to the machine at 45 sec and the calcium mobilization was 
recorded for an additional 4-9 minutes, depending on the cell type and 
experiment. For some experiments, calcium mobilization from intracellular stores 
was analyzed by addition of 4 mM EGTA (152). 
 To determine how LPA is affected by culture with various media additives, 
16:0 ester- or ether-LPA was used cultured at a high concentration (420 µM) in 
culture media (IMDM) so that it could be subsequently used at 20 µM in a 
calcium mobilization assay. LPA was cultured in media alone or media 
supplemented with 5% fatty acid-free BSA, 5% FBS, or 50 µM β-
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mercaptoethanol for 3 or 6 hours. The supernatant was then collected and 
aliquots of the supernatant were used as a source of LPA at a final 
concentration of 20 µM LPA (based on original LPA concentration) for calcium 
mobilization assays with C57BL/6 splenic B cells stimulated with anti-IgM. As a 




Erythrocyte-lysed splenocytes and pooled LN cells were sorted for 
Thy1+CD8+CD4- cells using the MoFlo XDP sorter (Beckman Coulter) to >85% 
purity. RNA was isolated using TRIzol (InvitrogenLife Technologies) and further 
purified of DNA with a DNA-free kit (Ambion). cDNA was prepared from 
equivalent amounts of RNA using a SuperScript III First-Strand Synthesis 
System for RT-PCR (Invitrogen Life Technologies). Quantitative PCR 
amplification was performed using Platinum SYBR Green qPCR SuperMix-UDG 
(Invitrogen Life Technologies) and detected on an MJ Research DNA Engine 
Opticon 2 real-time PCR machine.  
Primers for the Lpar1-3,6 receptors and Hprt were designed and then 
purchased (Integrated DNA Technologies) with the following sequences:  
Lpar1–sense  CTGTGGTCATTGTGCTTGGTG,  
Lpar1–antisense CATTAGGGTTCTCGTTGCGC,  
Lpar2–forward  GGCTGCACTGGGTCTGGG,  
Lpar2–sense  GCTGACGTGCTCCGCCAT,  
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Lpar3–sense  GCGCACAGGAATGGGAGAG,  
Lpar3–antisense  GAGCTGGAGGATGTTGGGAG,  
Lpar6-sense   TCTGGCAATTGTCTACCCATT,  
Lpar6-antisense  TCAAAGCAGGCTTCTGAGG,  
Hprt-sense   CTGGTGAAAAGGACCTCTCG,  
Hprt-antisense  TGAAGTACTCATTATAGTCAAGGGCA.  
Primers from Lpar4 and Lpar5 were purchased (Super Array Biosciences). 
The control for Lpar1-6 expression was thymus tissue. qPCR for Lpar6 was run 
separately, therefore expression was normalized to Lpar5 expression. The cycle 
threshold (Ct) was determined for each experiment based on background from 
control samples (no cDNA) and expression of Lpar mRNA of interest was 
normalized to Hprt mRNA. 
 
Flow cytometry 
 Cells were stained in 2% BSA-PBS+0.1% sodium azide with blocking Fc 
receptor antibody (2.4G2) on ice for 20-30 minutes. For live/dead assessment, 
the viability dye, 7-AAD, was added 10 minutes prior to data acquisition. All flow 
cytometric analysis was performed on the LSRII flow cytometer (BD) and 
analyzed with FlowJo v8 (Tree Star) and GraphPad Prism software (v 5.0). 
 The staining panel for analysis of proliferation by CFSE dilution was as 
follows: FcR block (2.4G2, homemade), CD8-eFluor450 (53-6.7, eBioscience), 
CFSE (CFDA, SE, Invitrogen), 7-AAD (eBioscience), CD25-APC (PC61.5, 
eBioscience), CD45.1 PE-Cy7 (A20, eBioscience), CD44 APC-eFluor780 (IM7, 
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eBioscience), and CD45.2-Alexa Fluor 700 (104, eBioscience) if needed to 
distinguish CD45.1+/+ from CD45.1+/-, as for in vivo cytotoxicity assays.  
 The staining panel for analysis of intracellular cytokine production was as 
follows: FcR block, CD8-eFluor450, TNFα-FITC (MP6-XT22, eBioscience), IL-2-
PE (JES6-5H4, eBioscience), and IFNγ-APC (XMG1.2, eBioscience) or Lamp-1 
(eBio1D4B, eBioscience) and Granzyme B-Alexa Fluor 647 (16G6, eBioscience).  
 The staining panel for OT-I typing was as follows: FcR block, CD8-
eFluor450, CD45.2-AF488 (104, Biolegend), Vβ5-PE (MR9-4, BD), Thy1.2-
PerCP (53-2.1, BioLegend), Vα2-APC (B20.1, eBioscience), and CD45.1 PE-Cy7 
(A20, eBioscience). 
Additional flow cytometry antibodies used include the following: CD8-APC-
eFluor780 (53-6.7, eBioscience), CD8-APC (53.6.7, BD), Thy1.2-APC (53-2.1, 
eBioscience), CD4-FITC (RM4-4, BD), CD62L-FITC (MEL-14, eBioscience), 
CD127-PE (A7R34, eBioscience), CCR7-PE (4B12, eBioscience), KLRG1-FITC 
(2F1, eBioscience), PD-1-FITC (29F.1A12, BioLegend), MHCII-Fluos (M5-114, 
homemade), CD86-APC (GL1, eBioscience), anti-SIINFEKL in H-2Kb (25-D1.16, 
gift of John Kappler), and CD3-FITC (145-2c11, eBioscience). 
 
Lipid preparation 
 Ether-LPA (16:0 AGP, Avanti Polar Lipids) and ester-LPA (16:0, Avanti 
Polar Lipids) were solubilized to a 5 mM concentration in 0.1% BSA-PBS, 
aliquoted, and stored at -20°C. Aliquots were diluted to 1 mM in RPMI 1640 
medium supplemented with 2.5% charcoal-stripped fatty acid-free BSA (faf-BSA 
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[Calbiochem]) prior to use in calcium mobilization assays. Faf-BSA still contains 
low levels of lipids that were stripped with charcoal. Charcoal-stripped faf-BSA 
was prepared by incubation of 10 mL of 1 mM faf-BSA in PBS with 1 mg of 
activated charcoal (Sigma) overnight at 4°C. Charcoal was removed by 
centrifugation and sterile filtration. 
 Ether- and ester-LPA were compared in a preliminary experiment in B 
cells to determine efficiency of inhibition of calcium mobilization, given that B 
cells express LPA5, which is preferentially stimulated by ether-LPA over ester-
LPA (110, 156). Ether-LPA was found to have a greater inhibition of calcium 
mobilization in splenic B cells (Figure 2.2), consistent with the ability of LPA5 to 




Figure 2.2 Inhibition of calcium mobilization by ether- 
versus ester-LPA 
Intracellular calcium mobilization was assessed in splenic B cells 
stimulated with 10 µg/mL anti-IgM in the absence (black line) or presence 
of 20 µM 16:0 ester-LPA (red line) or ether-LPA (blue line). 
 
 
 OTP was generated as previously described (157), stored as a powder, 
and solubilized in 95% methanol to create aliquots. Virgin glass tubes and caps 













were sterilized by autoclave and aliquots of 0.25 to 1µmol were prepared with 
glass pipettes (lipids readily adhere to plastic). Aliquots were allowed to 
desiccate sterilely to a film in a tissue culture hood. The concentration was 
confirmed by phosphorus assay (158). 
OTP was solubilized for experimental use by sonication with FBS- or 
charcoal-stripped faf-BSA-containing culture media or vehicle (2% propanediol, 
1% ethanol in PBS) for in vitro or in vivo usage, respectively. For in vitro 
experiments, OTP was prepared at 50 µM and passed through a 0.2 µm filter for 
further sterilization. For in vivo experimentation, solubilized OTP was transferred 
to siliconized eppendorf tubes and animals were dosed at 5 mg/kg every 8 hours. 
 
Transwell assay 
 C57BL/6 splenocytes (106 cells) were added to the upper chambers of 
Transwells (pore size, 5 µm; Costar) and were allowed to migrate for 3 h at 
37°C. For analysis of the chemokinetic response of T cells, cells were incubated 
with 1 µM LPA in the upper, lower, or both chambers. CXCL12 (50 ng/ml) was 
used as a lymphocyte chemoattractant positive control. Migrated cells were 
quantified by flow cytometry for B (B220+) and T cells (CD3+). 
 
In vitro T cell proliferation and activation assays 
 To determine if LPA affected activation of wild-type CD8+ T cells, C57BL/6 
splenocytes were erythrocyte-lysed and stimulated with 0, 1, or 10 µg/mL plate-
bound anti-CD3 and 0 or 1 µg/mL soluble anti-CD28 in 5% BSA RPMI in the 
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presence of 0, 1, or 10 µM LPA for 24 hours. Cells were harvested and stained 
for flow cytometry. 
OT-I splenocytes were isolated, erythrocyte-lysed, and labeled with CFSE 
(Invitrogen). For all CFSE labeling, cells were suspended at 15 x 106 / mL in PBS 
and CFSE was added to a final concentration of 2.5 µM for 10 minutes and then 
excess CFSE was removed by media washes. Splenocytes were pulsed with 1 
µM of the SIIGFEKL (G4, Anaspec, Inc.) or SIINFEKL (gift of Pippa Marrack) 
peptide for 4 hours or 90 minutes, respectively, in 5% faf-BSA RPMI with or 
without 50 µM OTP, then washed. Cells were plated at 2.5 x 106 cells/mL with or 
without 50 µM OTP in 96 well plates. Cells were enumerated by flow cytometry 
by counting gated events for the first minute of acquisition after event rate had 
stabilized. The proportion of cells that had proliferated was calculated by Flowjo 
analysis. The mean fluorescent intensity (MFI) values of activation marker 
expression were normalized to account for variations between experiments. 
To determine if antigen presentation was affected by LPA signaling, 
splenocytes from a T cell-deficient mouse (TCRα–/–) were pulsed with 1 µM 
SIINFEKL peptide in the presence or absence of OTP, washed, and used to 
stimulate purified CD8+ OT-I T cells (2:1, splenocytes:T cell) in culture in the 
presence or absence of OTP. 
 
In vitro effector function assays 
To assess in vitro cytokine production, OT-I effector T cells were 
generated in vitro by pulsing erythrocyte-lysed OT-I splenocytes with 1 µM 
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SIINFEKL and culture with IL-2 for 5 days. On day 5 of culture, target cells (EL4 
cells) were pulsed with 1 µM SIINFEKL and cultured at an effector to target ratio 
of 0.625:1 with OT-I effector T cells for 4 hours in the presence of Brefeldin A, in 
the presence or absence of 50 µM OTP. 
To compare in vitro cytokine production of LPA5-sufficient and LPA5-
deficient T cells, CD8+ T cells were purified from LPA5+/+ or LPA5–/– OT-I 
splenocytes and lymph nodes, and combined at a 1:2 ratio with C57BL/6 
splenocytes before a 4 hour pulse with SIIGFEKL (G4) peptide. Cells were 
washed and plated at 2.5 x 106 cells/mL. On day 3, cells were transferred to a 
round-bottom plate and cultured for 5 hours in the presence of brefeldin A. Cells 
were fixed, permeablized, and stained for flow cytometry. 
 To assess in vitro cytotoxic ability, OT-I effector T cells were generated as 
described before. Target EL4 cells were fluorescently labeled CFSEhigh with 2.5 
µM CFSE and pulsed with 10-100 nM SIINFEKL. Control EL4 cells were not 
pulsed with peptide and fluorescently labeled CFSElow by diluting the CFSE stain 
9-fold. CFSEhigh and CFSElow EL4 cells were mixed at a 1:1 ratio and combined 
with OT-I effector T cells at various effector to target (E:T) ratios. As an 
alternative method to assess cytotoxicity, target EL4 cells were not stained with 
CFSE and were pulsed with 10 nM SIINFEKL and combined with OT-I effector T 
cells at various effector to target (E:T) ratios. Cell death was assessed by Non-
Radioactive Cytotoxicity Assay (LDH ELISA, CytoTox 96, Promega) and adjusted 
for background lysis of OT-I T cells co-cultured with EL4 cells without SIINFEKL 
peptide (159). 
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Generation of bone marrow-derived dendritic cells 
 Gender-matched bone marrow-derived dendritic cells (BMDC) were 
generated by flushing of femur and tibia and culture at 106 cells/mL in RPMI 1640 
supplemented with 20 ng/mL GM-CSF (gift from Dr. Ross Kedl), 10% FBS 
(Omega Scientific), Penicillin-Streptomycin (Invitrogen), and GlutaMAX 
(Invitrogen). Media was refreshed on days 2 and 4 of culture. On day 7, BMDC 
were harvested from culture and stimulated with 1 ng/mL LPS for 90 minutes and 
pulsed with peptide for the last hour of LPS treatment. BMDC were washed 5 
times with media to remove LPS and peptide before use. 
 
In vivo SIINFEKL-BMDC stimulation 
Bone marrow derived dendritic cells were generated as described in 
section 2.8. One day prior to immunization, CD8+ T cells were purified from OT-I 
spleen and LN cells with a CD8+ magnetic bead enrichment kit (Isolation Kit II, 
Miltenyi) to a purity of ≥95%, and 106 CFSE-labeled CD8+ T cells were 
transferred to CD45 allotype mismatched recipient C57BL/6 mice. BMDC (106) 
were suspended in PBS and transferred by sub-cutaneous (s.c.) injection in the 
scruff to individual recipients. On d3 post-immunization, animals were sacrificed 
and dLN (axilary, brachial, cervical), ndLN (inguinal, mesenteric), and spleen 
were harvested. After erythrocyte lysis, cells were counted by Z2 Coulter Particle 
Count and Size Analyzer (Beckman-Coulter) and 10 x 106 cells were stained for 
flow cytometry. Cells were suspended in FACS buffer and stained with 7-AAD for 
viability before analysis on the BD LSRII. 
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IL-2 ELISA 
To determine IL-2 production of LPA5-sufficient versus LPA5-deficient OT-I, 
CD8+ T cells were purified from pooled splenocytes and lymph nodes from 
LPA5+/+ or LPA5–/– OT-I mice. 105 CD8+ T cells were cultured with SIINFEKL-
pulsed BMDC at a 2:1 or 10:1 ratio. Supernatants were collected at the indicated 
timepoints and assayed for IL-2 by ELISA. Briefly, wells were coated with anti-IL-
2 (JES6-1A12, eBioscience) and samples were detected with biotinylated anti-IL-
2 (JES6-5H4, BD) and AP-avidin (Southern Biotech). 
To determine IL-2 consumption of LPA5-sufficient versus LPA5-deficient 
OT-I, an in vitro experiment was conducted similarly, except that 15 ng/mL rmIL-
2 was added to culture. 
 
B16.cOVA tumor transfer 
 The OVA-transfected B16 tumor cell line (B16-OVA) was kindly provided 
by Dr. Ross Kedl. Cells were maintained in RPMI 1640 (Cellgro), supplemented 
with 10% heat-inactivated FBS (Omega Scientific), GlutaMAX, Penicillin-
Streptomycin, MEM NEAA, sodium pyruvate (Invitrogen), and 0.75 mg/mL G418 
sulfate selection (Cellgro). Cells were passaged after trypsin digestion every 2 
days. 
To determine how LPA5–/– OT-I T cells responded to tumor, 5 x 105 
B16.cOVA cells were transferred s.c. into the hind leg of recipients and 5 days 
later 106 CFSE-labeled OT-I T cells were transferred s.c. into the tail vein. 
Recipients were sacrificed 5 days later and tumor and dLN were harvested. 
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Lymphoid organs were mashed through a cell strainer (100 µm, BD), erythrocyte-
lysed, and counted. Tumors were digested in 0.5 mg/mL Collagenase D (Fisher 
Scientific) and 60 U/mL DNase (Sigma-Aldrich) for 30 minutes with perturbation 
every 10 minutes, then neutralized with 5 mM EDTA for 5 minutes. Tumor cells 
were homogenized by pipette and passed through a 100 µm filter, erythrocyte 
lysed, and counted. 
To measure OT-I CD8+ T cell control of tumor progression, 105 B16.cOVA 
cells were delivered s.c. into the leg of a C57BL/6 recipient mouse. On d5, 0.5 x 
106 OT-I T cells were transferred i.v. via tail vein injection. Tumor diameter was 
measured with calipers and body weight and overall appearance were assessed 
every 2 days. Mice were sacrificed when tumor diameter exceeded 10 mm.  
 
In vivo cytotoxicity assay with tumor burden 
C57BL/6 recipients were implanted s.c. in the leg with 0.5 x 105 B16.cOVA 
cells.  Five days post-implantation, 106 CFSE-labeled LPA5+/+ or LPA5–/– OT-I 
CD8+ T cells were transferred i.v. C57BL/6 splenocytes were divided to two 
populations and one population was labeled CFSEhigh and pulsed with SIINFEKL 
and the second population was labeled CFSElow and not pulsed with peptide. The 
CFSEhigh and CFSElow cells were combined at a 1:1 ratio and injected i.v. 1 day 
before harvest. Tumors and dLNs were harvested as before described and the 





 All statistical analyses were performed with FlowJo (v8, Tree Star) or 
GraphPad Prism software (v 5.0) using a two-tailed unpaired Student’s t test or 











LPA SIGNALING INHIBITS CD8+ T CELL ACTIVATION AND 
PROLIFERATION VIA LPA5 
 
Introduction 
Lysophosphatidic acid (LPA) is a bioactive lysophospholipid found in all 
eukaryotic tissues and in blood (57). Lysophospholipids, including LPA and 
sphingosine 1-phosphate (S1P), induce a diversity of biological and 
pathophysiological effects by binding and activating specific G-protein coupled 
receptors (GPCR) (63, 87, 103). Similar to S1P, the LPA lysophospholipid is 
recognized by a set of GPCR that are differentially expressed by different cell 
types and that are divided into two groups based on similarity: LPA1,2,3 belong to 
the Edg family of receptors whereas LPA4,5,6 belong to a purinergic-like family of 
receptors (60, 63). While S1P is now recognized to play an important role in 
orchestrating lymphocyte development, trafficking and function (137-142), the 
immune regulatory activities of LPA have been less studied despite the finding 
that many immune cells express LPA receptors (57, 87, 103).  
LPA is primarily generated in vivo via an extracellular lysophospholipase D, 
autotaxin (ATX), which has been proposed to associate with the cell surface and 
directly release LPA to receptors, thus efficiently initiating LPA signaling to that 
cell (91-94). LPA levels in healthy individuals is the result of synthesis by ATX 
and degradation of LPA by lipid phosphate phosphatases (81-83) and 
  35 
physiological levels of LPA are maintained in the hundred nanomolar range in 
plasma (62, 63). However, elevated LPA levels in the micromolar range have 
been reported in certain pathological conditions, such as inflammatory disease 
and in individuals with certain tumors (161) and given the expression of LPA 
receptors on immune cells, we sought to determine how the increase in LPA may 
affect the adaptive immune response. 
 T cell activation is induced by TCR signaling initiated by the appropriate 
MHC-peptide complex on an APC (10, 11). This activation can be modulated by 
TCR co-receptors in a positive (e.g. CD28, ICOS) or negative manner (e.g. 
CTLA-4, PD-1) (13-15, 17). In previous studies of B cells in our lab, we found that 
LPA signaling dampened calcium mobilization in primary B cells and B cell lines 
(152, 162). Thus, we questioned if LPA signaling could be an additional 
mechanism that modulates TCR signaling and activation. 
 We have further found that retroviral shRNA knock-down of LPA5 
dampened inhibition of LPA (152, 162). We substantiate this finding by showing 
that LPA5-deficient B and T cells are insensitive to LPA inhibition. Additionally, 
our lab found that LPA inhibited B cell activation and dampened antibody 
production in vivo (152). Given that LPA more potently inhibited calcium 
mobilization in CD8+ T cells than in B cells, we hypothesized that this inhibition of 
activation would be more pronounced in CD8+ T cells.  Our data demonstrate 
that LPA signaling can profoundly inhibit T cell activation and proliferation in 
response to peptide stimulation and that this inhibition is stronger with a weaker 
affinity peptide. Finally, we show that these findings translate to in vivo relevance, 
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as treatment with an LPA analog results in inhibition of CD8+ T cell activation in 
response to stimulation with peptide-loaded dendritic cells. 
 
Results 
LPA signaling inhibits TCR-mediated calcium mobilization in CD8+ T cells  
via LPA5 
By measuring intracellular calcium mobilization by flow cytometry we can 
determine the immediate effects of LPA on activation simultaneously in different 
cell types. We previously found that LPA signaling dampens B cell calcium 
mobilization in response to BCR signaling (152) and that ether-LPA was a more 
potent inhibitor than ester-LPA (Figure 2.2). Given the many similarities in 
antigen receptor signaling by B and T lymphocytes, we questioned if LPA 
similarly inhibited TCR signaling. LPA is present in plasma in the nanomolar 
range however is found at micromolar concentrations in serum and in the ascites 
fluid of patients with certain cancers (63, 117, 163). Therefore, we tested the 
influence of 1-20 µM concentrations of 16:0 ether-LPA on TCR-mediated 
intracellular calcium mobilization. The CD3 molecule is a component of the T cell 
receptor complex and T cells can be activated by engaging CD3 molecules with 
anti-CD3 antibody and subsequent crosslinking with an anti-IgG antibody or 
streptavidin (the latter with biotinylated anti-CD3) (155). The results from these 
experiments revealed that LPA inhibited intracellular calcium mobilization not 
only in marginal zone and follicular B cells, as we had previously shown, but also 
in both CD4+ and CD8+ T cells in response to TCR stimulation achieved by anti-
CD3 monoclonal antibody (mAb) crosslinking (Figure 3.1). LPA treatment in the 
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absence of antigen receptor stimulation did not affect calcium mobilization. 
Interestingly, when inhibition of calcium mobilization of similar magnitude was 
compared across lymphocyte subsets, we found that LPA inhibition appeared 
most pronounced in CD8+ T cells (Figure 3.1). We therefore decided to elucidate 
the mechanism of LPA-mediated dampening of calcium mobilization in CD8+ T 





Figure 3.1  LPA dampens calcium mobilization in major 
splenic lymphocyte populations 
Intracellular calcium mobilization was assessed in splenic B (marginal 
zone, MZ; follicular, FO) and T cells stimulated with 10 µg/mL anti-IgM or 
10 µg/mL anti-CD3, respectively, with or without 20 µM 16:0 ether-LPA 
(thin and bold lines, respectively).  20 µM LPA treatment in the absence of 
antigen receptor (AgR) stimulation is shown in gray lines. Representative 
of at least 5 independent experiments. 
 
To determine if LPA inhibition of calcium mobilization occurred directly on 
CD8+ T cells, we repeated the calcium mobilization assay with purified CD8+ T 
cells and found that LPA inhibition was cell-intrinsic (Figure 3.2). We titrated the 





























































































amount of LPA used in the calcium mobilization assay to determine the 
sensitivity of inhibition and found that inhibition was achieved with all 
concentrations tested, was dose dependent, and inhibition was sensitive to LPA 




Figure 3.2  LPA inhibition of CD8+ T cell calcium 
mobilization is dose dependent 
Intracellular calcium mobilization was assessed in purified splenic and 
pooled lymph node CD8+ T cells stimulated with 10 µg/mL anti-CD3 in the 
absence (black line) or presence of the indicated concentrations of LPA. 
Representative of 4 independent experiments. 
 
In B cells, we have shown that LPA inhibition of BCR signaling manifests 
by reducing intracellular calcium stores release (152). To determine if LPA 
signaling similarly affected intracellular calcium release after TCR stimulation, 
purified CD8+ T cells were stimulated in the presence of EGTA to selectively 
monitor release of calcium from intracellular stores. These results revealed that 
in the absence of extracellular calcium, LPA maintained ability to inhibit an 
increase in intracellular calcium levels, even at the lowest LPA concentration 
tested (1µM, Figure 3.3). These results suggest that LPA inhibits TCR-induced 



















Figure 3.3  LPA treatment dampens calcium release from 
intracellular calcium stores 
Intracellular calcium mobilization was assessed in the presence of 4 mM 
EGTA to prevent extracellular influx. Purified splenic and pooled lymph 
node CD8+ T cells were stimulated with 10 µg/mL anti-CD3 in the absence 
(black line) or presence of the indicated concentrations of LPA. 
Representative of 2 independent experiments. 
 
We next wanted to determine the LPA receptor(s) responsible for this 
inhibition by first measuring LPA receptor expression on CD8+ T cells. There are 
currently six described LPA receptors: LPA1-6 (96). Flow cytometric compatible 
antibodies to the extracellular region of murine LPA receptors are not 
commercially available therefore we evaluated LPA receptor expression by 
quantitative RT-PCR (qRT-PCR). These results revealed that purified CD8+ T 
cells express LPA receptors 2, 5, and 6 (Figure 3.4), similar to B cells (152) and 





















Figure 3.4  CD8+ T cells express Lpar1, 5, and 6 
Expression of Lpar1-6 in purified splenic and lymph node CD8+ T cells as 
measured by qRT-PCR. PCR control is thymus tissue. Representative of 
1-3 independent experiments. 
 
It had previously been shown in our lab that LPA5 knockdown by retroviral 
shRNA resulted in the A20 B cell line reduced sensitivity to LPA inhibition (152). 
To determine which of these LPA receptor(s) was responsible for LPA inhibition 
in T cells, we compared calcium mobilization in splenocytes from LPA2–/– and 
LPA5–/– mice (LPA6–/– mice were not commercially available). We found that 
although LPA inhibition was intact in the LPA2-deficient CD8+ T cells, this 
inhibition was ablated in the LPA5-deficient CD8+ T cells, demonstrating that 




























Figure 3.5  Inhibition of calcium mobilization by LPA is 
ablated in LPA5–/– CD8+ T cells 
Intracellular calcium mobilization was assessed in LPA2–/– or LPA5–/– 
splenic CD8+ T cells in response to 10 µg/mL anti-CD3 stimulation in the 
presence (bold line) or absence (thin line) of 20 µM LPA. Representative 
of 2 independent experiments 
 
LPA5-deficient B cells (B220+) and CD4+ T cells were also resistant to LPA 
inhibition of calcium mobilization (Figure 3.6A, right panels). Interestingly, LPA5 
heterozygous mice had an intermediate phenotype of calcium inhibition by LPA 
for all three cell types tested (Figure 3.6A, center panels). This intermediate 
phenotype is emphasized when the 20 µM treated calcium traces (bold lines in 
Figure 3.6A) were overlaid (Figure 3.6B). This indicates that a single copy of the 
Lpar5 gene is sufficient to transmit inhibitory signaling, though not to the same 
extent as the LPA5+/+ homozygote. Further this suggests that a single copy of 
Lpar5 results in reduced surface expression of the LPA5 protein. Since we 
observed an intermediate phenotype for the heterozygous animals, we compared 
LPA5–/– mice with gender-matched littermate wild-type mice in all future 
experiments using LPA5–/– mice. 
 























































Figure 3.6  LPA5–/– T and B cells are resistant to LPA 
inhibition whereas LPA5+/– lymphocytes exhibit an intermediate 
phenotype 
(A) Intracellular calcium mobilization was assessed in LPA5+/+ (left column), 
LPA5+/– (center column), and LPA5–/– (right column) splenocytes as gated 
on CD8+ T cells (upper row), CD4+ T cells (center row), and B cells (B220+, 
bottom row), in response to AgR stimulation (20 µg/mL anti-IgM, 10 µg/mL 
anti-CD3) in the presence (bold line) or absence (thin line) of 20 µM LPA. 
Representative of 2 independent experiments. 
(B) Intracellular calcium mobilization was compared between LPA5+/+ (red 
line), LPA5+/– (blue line), and LPA5–/– (green line) splenocytes as gated on 
CD8+ T cells (left), CD4+ T cells (center), and B cells (B220+, right), in 
response to AgR stimulation in the presence of 20 µM LPA. 
Representative of 2 independent experiments. 
 
  


























































































LPA does not influence chemotaxis in naïve T cells 
 We had previously shown that LPA induced chemorepulsion in splenic B 
cells (Figure 1.4) and LPA has been shown to influence chemokinesis in T cells 
(132, 149, 151). We questioned whether LPA had an effect on chemotaxis of 
splenic T cells, similar to previously published. To address this question, we 
performed a Transwell assay with C57BL/6 splenocytes and tested whether the 
presence of LPA in the top chamber, bottom chamber, or both chambers 
influenced migration of naïve T cells (Figure 3.7). In contrast to our findings with 
B cells, the presence of 1 µM LPA in either the top or bottom chambers did not 
significantly influence T cell migration. This indicates that a low concentration of 
LPA does not cause chemotaxis or chemorepulsion in naïve splenic T cells. 
However we did not discriminate between CD4+ and CD8+ T cells in these 
experiments and cannot exclude that there may be a differential effect between T 
cell subsets. These data likely represent primarily CD4+ T cells, as CD4+ T cells 
outnumber CD8+ T cells in the spleen of 8-12 week old C57BL/6 mice (165). In 
addition, we cannot exclude that T cells may migrate differently to LPA when 
activated or differentiated to an effector T cell phenotype, or that increased levels 
of LPA may differently influence T cell migration. Altered chemotaxis to LPA as 
determined by activation state has been shown in other cell types, as immature 
DC are responsive to LPA chemotaxis however mature DC downregulate the 





Figure 3.7 LPA does not influence chemotaxis of naïve 
splenic T cells 
Transwell migration assay (5 µm pore size) of erythrocyte-lysed C57BL/6 
splenocytes added to the upper chamber with 1 µM LPA added either to 
the same chamber (to induce chemokinesis/chemorepulsion), to the lower 
chamber (to induce chemotaxis) or to both chambers (blue bars, n=3). 
After a 3h incubation at 37°C, T cells that had migrated to the bottom 
chamber were quantified by flow cytometry (CD3+). Right, CXCL12 (50 




Increased LPA signaling inhibits proliferation, accumulation, and activation of  
OT-I T cells in vitro 
Intracellular calcium is a critical downstream effector of antigen receptor 
signaling that leads to the activation of distinct transcriptional programs important 
for T cell activation and function (166, 167). Thus, we next wanted to assess if 
LPA dampening of TCR-induced calcium mobilization would lead to diminished 





















Upper  LPA  LPA  CXCL12  CXCL12 
Lower  LPA  LPA  CXCL12  CXCL12 
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degraded both in vitro and in vivo with a reported half-life as short as 3 minutes in 
the blood (66, 168), thus before using LPA in culture, we wanted to determine if 
our various media additives would contribute to LPA degradation. To test this, we 
cultured LPA at a high concentration (420 µM) with various media supplements 
such as fatty acid-free BSA (faf-BSA) and FBS, for 6 hours in the presence or 
absence of splenocytes. We then tested LPA for degradation by using the 
supernatant as the source of LPA at a calculated concentration of 20 µM in a 
calcium mobilization assay with splenic B cells and compared inhibition by 
cultured LPA versus stock LPA (Figure 3.8). We also compared the stability of 
the more commonly used ester-LPA with ether-LPA, as ether-LPA is reported to 
be more stable and LPA5 is preferentially engaged by ether over ester moieties 
of LPA (110, 169). We found that both LPA species incubated in faf-BSA 
maintained the ability to inhibit calcium mobilization, comparably to freshly 
thawed LPA (Figure 3.8). However, LPA incubated in FBS media for 6 hours was 
sufficient to ablate inhibition of calcium mobilization. These results indicated that 
a factor (likely LPP) is present in FBS that degrades LPA. In follow-up studies, 
we found that similar to faf-BSA, BSA did not affect the ability of LPA to inhibit 
calcium. However a common additive for in vitro mouse cell culture, β-
mercaptoethanol, degraded the signaling ability of LPA similar to FBS (data not 
shown), thus we elected to not supplement media with β-mercaptoethanol for 
future in vitro experiments. Additionally, we did not see a difference when LPA 
was incubated with splenocytes, indicating that LPA degradation or preservation 




Figure 3.8 The ability of LPA to inhibit calcium mobilization 
is ablated by culture in FBS-media 
Ester- or ether-LPA was used fresh (top panel) or cultured at 420 µM in 
culture media (IMDM) supplemented with fatty-acid free BSA (faf-BSA, 
center panel) or FBS (lower panel) for 6 hours. The supernatant was then 
collected and aliquots of the supernatant were used as a source of LPA at 
a final concentration of 20 µM LPA (based on original LPA concentration) 
for calcium mobilization assays with splenic B cells stimulated with anti-
IgM (indicated by arrow). As a control, cells were treated with media 




With these results, we first examined proliferation of splenic CD8+ T cells 
in BSA-media, as we had found that BSA-media did not readily degrade LPA. We 
stimulated CFSE-labeled CD8+ T cells and assessed proliferation after 3 days. 
However, we found that BSA-media was insufficient to support CD8+ T cell 








































proliferation in response to anti-CD3 stimulation, whereas CD8+ cells cultured in 
FBS-media were able to proliferate (Figure 3.9). Although BSA-media was 
insufficient to support T cell proliferation, we found that it was sufficient to support 
CD8+ T cell activation for 1 day of culture, thus we next compared CD8+ T cell 
activation in the presence or absence of LPA after a day of stimulation.  
 
 
Figure 3.9 Media supplemented with BSA is insufficient to 
support T cell proliferation in vitro 
C75BL/6 splenic CD8+ T cells were purified by magnetic bead separation 
and labeled with CFSE before stimulation with 10 µg/mL plate-bound anti-
CD3 for 3 days in media supplemented with 5% FBS (left panel) or 5% 
BSA (right panel).  
 
 
To determine how CD8+ T cell activation was affected by LPA signaling in 
vitro, we stimulated splenic CD8+ T cells with anti-CD3 in the presence or 
absence of LPA, and examined CD62L (L-selectin) expression, which is found at 
high levels on naïve and memory T cells, but is downregulated upon activation in 






































activation, but only with suboptimal levels of activation (Figure 3.10). Specifically, 
while LPA had no effect on CD62L expression in the absence of stimulation (left 
histogram), LPA treatment inhibited downregulation of CD62L upon activation 
with 1 µg/mL anti-CD3 (center histogram), but not at 10 µg/mL anti-CD3 (right 
histogram). This suggested to us that the negative regulatory function of LPA 




Figure 3.10  LPA treatment inhibits activation with 
suboptimal stimulation 
C57BL/6 splenocytes were cultured in BSA-media for 24 hours with 
(center and right histograms) or without (left histogram) indicated plate-
bound anti-CD3 and soluble anti-CD28, in the presence (blue and green 
lines) or absence of LPA (red line, gray filled). Data shown is gated on 
CD8+ T cells. Representative of 2 independent experiments. 
 
 
As we had encountered difficulties using LPA in vitro, we decided to 
continue experiments with the metabolically stable LPA analog, octodecenyl 
thiophosphate (OTP) to induce LPA signaling, similar to that achieved previously 
in vivo (68, 69). OTP is not degraded by LPP1 and the absence of the glycerol 
backbone prevents acylation by lysophosphatidate transacetylases (68). 


































Importantly, OTP is preferentially recognized by LPA5 compared to LPA and 
engages LPA5 at a lower EC50 than other LPA receptors (68, 171). Additionally, 
since we found that inhibition by LPA was most evident at lower levels of 
stimulation, we elected to use a T cell receptor transgenic mouse to allow a more 
physiological stimulation with a specific peptide instead of monoclonal antibody 
treatment. The OT-I T cell receptor (TCR) transgenic mouse is a well-
characterized model that features CD8+ T cells that express a TCR specific for 
the chicken ovalbumin peptide, SIINFEKL. Through use of this model, we were 
able to modulate the strength of stimulation by use of different peptides (23). 
Surface plasmon resonance studies have revealed that wild-type TCR affinities 
range from 1-100 µM (172). The OT-I TCR has an affinity for the SIINFEKL 
peptide of KD=6.5 µM but also recognizes altered peptide ligands, such as 
SIIGFEKL (G4) (172) with weaker affinity (KD ~10 µM). 
Using this in vitro system we monitored CD8+ T cell proliferation and 
expression of activation markers after peptide stimulation in the absence or 
presence of OTP. To achieve this, C57BL/6 splenocytes were isolated and 
labeled with the intracellular fluorescent dye, carboxyfluorescein succinimidyl 
ester (CFSE) and T cell proliferation was monitored by the dilution of CFSE in 
dividing CD8+ T cells. When CFSE-labeled OT-I splenocytes were stimulated 
with G4 peptide, CD8+ T cells were acutely inhibited in proliferation in the 
presence of OTP (Figure 3.11). By day 3 control cells had typically started to 
divide with the majority having undergone at least 2 divisions by day 7 while the 





Figure 3.11  LPA signaling ablates OT-I proliferation to G4 
peptide stimulation 
OT-I splenocytes were labeled with CFSE, stimulated with G4 peptide and 
cultured for 1-7 days. At each indicated timepoint, cells were harvested, 
stained and data shown is from gated viable CD8+ T cells. CD8+ T cells 
were analyzed for the expression of CD25 (Y-axis) and CFSE 
fluorescence (X-axis) at the indicated times. CD8+ T cells were left 
untreated (upper row) or OTP treated (middle row). Overlay of CFSE 
histograms by day are shown in bottom row in the absence (thin line) or 
presence of OTP (bold line) or when left unstimulated (gray filled). 
Representative of 3 independent experiments. 
 
Furthermore, and as indicated in Figure 3.11, expression of the activation 
marker, CD25, was also depressed in OTP-treated cells. Direct comparison of 
the T cell activation markers, CD25 and CD44, after in vitro TCR stimulation 
revealed inhibited expression with OTP treatment (Figure 3.12A). As a 
consequence of this inhibition of activation and proliferation, OTP treatment also 
resulted in reduced accumulation of CD8+ T cells (Figure 3.12B) without a 

































































































































































































































































































































































Figure 3.12  Increased LPA signaling inhibits activation and 
prevents accumulation of CD8+ T cells in vitro 
(A) CD25 and CD44 expression on OT-I CD8+ T cells is shown in 
histograms after 3 or 4 days, respectively, of in vitro culture in the absence 
of stimulation (gray filled) or after G4 peptide stimulation alone (thin line), 
or in the presence of OTP (bold line).  Histograms are representative of 3 
independent experiments and are summarized in bar chart (Mean + SEM). 
(B) Enumeration of in vitro cultured OT-I CD8+ T cells at the indicated 
times in the absence of G4 (grey circles) or after G4 stimulation alone 
(open circles) or in the presence of 20 µM OTP (black circles).  
(C) Cell viability was determined by 7-AAD staining at the peak of CD25 




 Given that proliferation and CD25 (high affinity IL-2 receptor chain) 
expression are affected by IL-2 signaling (173), we questioned if LPA or OTP 
treatment was inhibiting the CD8+ T cell response independently of TCR and LPA 
receptor signaling. We wanted to confirm that LPA or OTP was not affecting 
proliferation and activation merely by preventing IL-2 binding to the IL-2 receptor 



















































































































cell line, which is a T cell line that is dependent on IL-2 but independent of TCR 
signaling for survival, and thus this cell line can be used to measure IL-2 activity 
in a sensitive manner in vitro (174).  We cultured HT-2 cells with titrated 
concentrations of IL-2 (0.06-1000 ng/mL [0.6-10,000 U/mL]) in the presence or 
absence of LPA or OTP to determine if these treatments interfered with IL-2 
signaling in this cell line. We found that LPA or OTP treatment did not affect HT-2 
survival, as cell death was observed at the same concentration of IL-2, 
regardless of the presence of LPA or OTP. This indicates that LPA or OTP does 
not interfere with IL-2 binding the IL-2R or IL-2 signaling independently of TCR 
signaling (data not shown).  
 
OTP treatment does not affect APC function and inhibits activation and 
proliferation to a lesser degree to a high affinity antigen 
In this in vitro system, activation of CD8+ T cells is dependent on 
presentation of the peptide in MHCI by splenic APC. Therefore, we wanted to 
determine if increased LPA signaling was affecting CD8+ T cell activation 
indirectly by interfering with peptide presentation by APC. By using a peptide for 
stimulation instead of whole antigen, the peptide can load externally into the 
binding groove of the MHC molecules expressed on the surface of the APC, 
rather than requiring internalization, processing, and internal peptide loading onto 
MHC as is required for whole antigen (175). However we wanted to confirm that 
LPA signaling was not interfering with external peptide loading into the MHCI 
molecule and thus altering the antigen presentation. To address this possibility, 
we pre-treated T cell-deficient splenocytes (TCRα–/–) with OTP while pulsing with 
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SIINFEKL peptide. We then washed away excess peptide and OTP and used 
these peptide-loaded APC to stimulate purified CD8+ OT-I T cells in the presence 
or absence of OTP. If OTP treatment did negatively impact peptide presentation 
by APC, we would expect a lower level of activation in CD8+ T cells stimulated 
with APC that had been pretreated with OTP. We found that CD8+ T cell 
activation was not affected by OTP pretreatment of APC, as shown by similar 
CD25 expression after co-culture of OT-I CD8+ T cells and SIINFEKL-pulsed 
TCRα–/– splenocytes (Figure 3.13). This indicates that OTP treatment does not 
interfere with peptide presentation by APC, however does not address if OTP 




Figure 3.13  OTP treatment does not affect peptide 
presentation 
Splenocytes from a T cell-deficient mouse (TCRα–/–) were pulsed with 
SIINFEKL peptide in the presence (black) or absence (white) of OTP, 
washed, and used to stimulate purified CD8+ OT-I T cells in culture in the 
presence or absence of OTP (n=1). 
 
 
Additionally, we wanted to compare the ability of OTP to dampen 

























found that LPA inhibition was greatest with suboptimal stimulation (Figure 3.10). 
Interestingly, we found that when we stimulated at a 100-fold lower concentration 
(10 nM) of a higher affinity peptide (SIINFEKL), we again observed inhibition of 
activation by OTP treatment but at a diminished capacity as compared to the 
inhibition of activation to the G4 peptide (Figure 3.11). Proliferation with OTP 
treatment appeared to delay proliferation by 1 division as compared to untreated 
OT-I CD8+ T cells and CD25 expression was dampened to a lesser degree than 
to G4 stimulation. This indicated that LPA inhibitory regulation of TCR signaling 




Figure 3.14  OTP treatment dampens OT-I activation and 
proliferation to the higher affinity peptide, SIINFEKL 
OT-I splenocytes were labeled with CFSE, stimulated with SIINFEKL 
peptide and cultured for 3 days. Viable CD8+ T cells were analyzed for the 
expression of CD25 and CFSE fluorescence in the absence (thin line) or 
presence of OTP (bold line) or when left unstimulated (gray filled) and is 
representative of 2 independent experiments. 
 
 
LPA signaling modestly inhibits effector function in vitro 
 As we had found that increased LPA signaling dampened activation, we 
questioned if LPA signaling also impacted the effector function of CD8+ T cells, 
















































towards a cell presenting specific peptide in the context of MHCI. In earlier 
experiments, we modulated LPA signaling during stimulation to determine how 
LPA signaling affected the transition of naïve to activated CD8+ T cells. In 
contrast, for these experiments we stimulated naïve CD8+ T cells to differentiate 
to effector T cells in vitro in the absence of additional LPA signaling and then 
tested how LPA signaling would affect subsequent re-stimulated effector 
functions. To generate effector CD8+ T cells in vitro, we pulsed OT-I splenocytes 
with SIINFEKL peptide, washed away excess peptide, and cultured the cells for 5 
days in the presence of IL-2. This treatment resulted in >90% CD8+ T cells that 
were CD25+ (data not shown). We then restimulated the effector CD8+ T cells 
with G4- or SIINFEKL-pulsed target cells (EL4 cells) and monitored CD8+ T cell 
production of the effector cytokines, TNFα and IFNγ. We were unable to detect 
intracellular cytokine production in response to G4-pulsed targets (data not 
shown), similar to published data that found no detectable intracellular IFNγ 
staining after co-culture with EL4 cells pulsed with 1 µM G4 (159). In response to 
SIINFEKL-pulsed cells, we found that OTP treatment had a modest effect on 
cytokine generation as determined by intracellular staining, inhibiting the 
proportion of cells expressing both cytokines by approximately 9% (Figure 3.15). 
This is similar to findings by another group who has found only a slight inhibition 
of IFNγ production with LPA treatment in human T cell lines (Paul Murray, 
personal communication). This indicates that LPA signaling has a negligible 





Figure 3.15  OTP treatment modestly dampens effector 
cytokine production 
OT-I effector T cells were generated in vitro by pulsing OT-I splenocytes 
with 1 µM SIINFEKL and culture with IL-2 for 5 days. On day 5 of culture, 
target cells (EL4 cells) were pulsed with SIINFEKL and cultured with OT-I 
T cells for 4 hours in the presence of Brefeldin A, in the presence (right 
panel) or absence (center panel) of OTP. Cells were permeabilized and 
stained for IFNγ and TNFα expression by flow cytometry. Representative 
of 2 independent experiments. 
 
 
 We next tested if LPA signaling affected the killing ability of effector OT-I 
CD8+ T cells. Similar to the cytokine production experiment, we generated 
effector OT-I CD8+ T cells in vitro and then co-cultured the effector cells with 
SIINFEKL-pulsed target cells (EL4 cells) and monitored killing of the target cells. 
To approach this question in congruence with our findings that inhibition by LPA 
signaling was most potent with suboptimal stimulation, we used low 
concentrations (10 or 100 nM) of SIINFEKL to pulse target cells prior to culture 
with effector OT-I CD8+ T cells (Figure 3.16). We further modulated killing by 
titrating the ratio of CD8+ effector T cells to target cells pulsed (Figure 3.16). We 
first examined the ability of OTP to inhibit killing of fluorescently labeled target 
cells (CFSEhigh) that were pulsed with SIINFEKL peptide as compared to 































































SIINFEKL. By flow cytometry, we were able to compare the two target cell 
populations and observe specific killing by the reduction in frequency of 
SIINFEKL-pulsed target cells as compared to control cells. With this assay, we 
determined that OTP treatment caused a slight decrease of specific killing by 
approximately ten percent (Figure 3.16A).  
We additionally attempted to determine differences in killing with G4-
pulsed target cells, however we were unable to achieve killing of said targets and 
were thus concerned that this assay may not be sensitive enough to detect small 
amounts of specific killing. Therefore we used a cytotoxicity detection kit that 
measures cell death by the release of lactate dehydrogenase (LDH) from lysed 
cells and has been used previously as a more sensitive assay to detect killing of 
up to a third of 1 µM G4-labeled targets by OT-I CD8+ effector T cells (159). 
However in our hands, we were unable to detect killing of G4-labeled targets. We 
were able to monitor killing of SIINFEKL-pulsed target cells and we again 
observed a slight decrease in cytotoxic activity by approximately ten percent over 
cytotoxicity measured from OT-I CD8+ T cells that were not treated with OTP 
(Figure 3.16B). Combined with the intracellular cytokine production experiments, 
we concluded that LPA signaling has a minor inhibitory effect on OT-I CD8+ T cell 





Figure 3.16  LPA signaling induces a minor inhibition of the 
killing ability of CD8+ T cells 
OT-I effector T cells were generated in vitro by pulsing OT-I splenocytes 
with 1 µM SIINFEKL and culture with IL-2 for 5 days. 
(A) Target EL4 cells were fluorescently labeled CFSEhigh and pulsed with 
100 nM SIINFEKL. Control EL4 cells were not pulsed with peptide and 
fluorescently labeled CFSElow. CFSEhigh and CFSElow EL4 cells were 
mixed at a 1:1 ratio and combined with OT-I effector T cells at the 
indicated effector to target (E:T) ratio. Killing was determined by the loss 
of CFSEhigh cells relative to CFSElow cells. Representative of 2 
experiments. 
(B) Target EL4 cells were pulsed with 10 nM SIINFEKL and combined with 
OT-I effector T cells at the indicated effector to target (E:T) ratio. Cell 
death was assessed by Non-Radioactive Cytotoxicity Assay (LDH ELISA) 
and adjusted for background lysis of OT-I T cells co-cultured with EL4 
cells without SIINFEKL peptide. Representative of 2 experiments. 
 
 
Increased LPA signaling dampens proliferation and activation of CD8+ T cells in 
response to SIINFEKL-BMDC stimulation in vivo 
Thus far, our in vitro data demonstrate that LPA signaling via LPA5 on 
CD8+ T cells inhibits TCR signaling, activation, and proliferation but only 
modestly suppressed cytotoxic activity. We next addressed whether this LPA 
regulatory pathway similarly operated on T cells in vivo. To accomplish this, OT-I 
CD8+ T cells were purified to >95% purity, CFSE-labeled, and transferred to 
C57BL/6 recipients. One day after T cell transfer, 106 bone marrow-derived 


































with 1 µM SIINFEKL or G4 peptide, washed, and transferred by sub-cutaneous 
(s.c.) injection to the scruff of recipient mice (Figure 3.18A). Transfer of peptide-
pulsed BMDC has been used by others to transiently introduce antigen in in vivo 
experiments (176) and we were able to measure activation by CFSE dilution in 
response to SIINFEKL-BMDC stimulation (Figure 3.18B). In contrast, transfer of 
BMDC pulsed with G4 peptide did not stimulate previously transferred OT-I CD8+ 
T cells as determined by the absence of increased activation antigen expression 
or proliferation (data not shown). In further attempts to activate transferred OT-I 
CD8+ T cells with G4-pulsed BMDC, we varied G4 peptide concentrations, the 
duration of BMDC peptide pulse, and tested different LPS treatment intervals to 
achieve maximal DC maturation as determined by CD86 and MHCII expression. 
Additionally, we confirmed G4 peptide loading of MHCI on the BMDC by flow 
cytometry with an antibody that recognizes SIINFEKL peptides within MHCI H2-
Kb (25-D1.16). We found similar expression with G4- and SIINFEKL-pulsed 
BMDC after 1-4 hours of peptide pulse and lower expression after overnight 
incubation with peptide, showing that increased incubation with peptide (over 1 
hour) did not improve peptide presentation and that presentation of G4 peptide 
was similar to SIINFEKL peptide (Figure 3.17). Nevertheless, with none of these 
conditions did we find that transfer of G4-pulsed BMDC resulted in activation of 




Figure 3.17 Peptide pulse of 1-4 hours results in equivalent 
expression of OVA peptide in H2-Kb 
BMDC were generated and pulsed with peptide for 1-4 hours or overnight, with 
LPS maturation for the final hour of incubation. BMDC were then stained with 25-
D1.16 antibody and analyzed for surface peptide presentation. 
 
 
In contrast, when 1 µM SIINFEKL-pulsed BMDC were transferred to 
recipient mice, OT-I CD8+ T cell proliferation was clearly observed 3 days later 
(Figure 3.18B) in the draining lymph nodes (dLN) of subcutaneous (s.c) transfer 
to the scruff of the mouse (axillary, brachial, cervical lymph nodes). This 
activation could be titrated by transfer of varying numbers of dendritic cells, with 
106 dendritic cells producing consistent, measurable proliferation in the 
transferred OT-I CD8+ T cells (Figure 3.18B). Interestingly, s.c. transfer of 
SIINFEKL-BMDC resulted in OT-I CD8+ T cell activation isolated to the dLN, as 
CFSE-diluted cells were not observed in non-draining lymph nodes (ndLN: 
inguinal, mesenteric lymph nodes) nor in the spleen (data not shown), indicating 
% of Max
















































that this was a local, but not systemic, method of activating transferred OT-I  
CD8+ T cells. Therefore the in vivo experiments of T cell activation relied on 





Figure 3.18  Schematic of peptide-BMDC transfer to induce 
proliferation of transferred OT-I CD8+ T cells 
(A) Schematic diagram of adoptive transfer of OT-I CD8+ T cells and in 
vivo OTP treatment. CD8+ OT-I T cells were isolated and 106 CFSE-
labeled cells were adoptively transferred intravenously to C57BL/6 
recipients one day prior to immunization.  One hour before s.c. transfer of 
106 SIINFEKL-pulsed BMDC, OTP (5 mg/kg) was administered s.c. and 
this dose was repeated every 8 hours. On day 3 after transfer of peptide-
loaded BMDC, mice were sacrificed and draining lymph nodes harvested 
for analysis. 
(B) Activation of transferred OT-I CD8+ T cells as in Fig. 3.14A is titrated 

















































 To enhance LPA signaling in vivo, we used OTP as previously reported 
(68, 69). Initial attempts with daily dosing of 1 mg/kg OTP did not affect OT-I 
CD8+ T cell activation (data not shown). However, we later learned that 
subcutaneous administration of OTP at 5 mg/kg results in detectable levels in the 
blood after 1 hour with an approximate half-life of 5.5 hours (Gabor Tigyi, 
personal communication). Thus, daily dosing of OTP was likely not adequately 
frequent to increase LPA receptor signaling. Therefore, in all future experiments, 
mice were treated with 5 mg/kg OTP every 8 hours, with the first dose preceding 
adoptive transfer of SIINFEKL-BMDC by 1 hour (Figure 3.18A). As a result, OT-I 
CD8+ T cells recovered from the dLN of OTP-treated animals 3 days after 
stimulation had proliferated to a significantly lesser extent than vehicle-treated 
animals (Figure 3.19A). Furthermore, in the dLN of OTP-treated mice, OT-I CD8+ 
T cells were present at decreased numbers relative to vehicle-treated animals 
treated with OTP, likely as a result of the inhibited proliferation. In addition, in the 
OTP-treated recipients, OT-I CD8+ T cells were less activated compared to 
vehicle-treated mice as determined by CD25 expression (Figure 3.19C). Taken 
together, our data demonstrate that increased LPA signaling using OTP inhibits 
OT-I CD8+ T cell proliferation and activation to antigen-specific stimulation both in 










3.19   LPA signaling inhibits TCR-mediated CD8+ T cell 
activation in vivo 
Experiment was conducted as diagrammed in Fig. 3.18. Data shown are 
of OT-I CD8+ T cells in the dLN and are representative of 2 independent 
experiments (n=4/group, mean + SEM). 
(A) Histograms of CFSE dilution in vehicle-treated (thin line), OTP-treated 
(bold line), and unstimulated control (gray filled) OT-I CD8+ T cells. 
(B) Number of OT-I CD8+ T cells in dLN. 
(C) Representative histograms of CD25 expression by OT-I CD8+ T cells 
after vehicle-treatment (thin line), OTP-treatment (bold line) or 
unstimulated (grey shaded). Right panel shows expression of CD25 as 
mean fluorescence intensity (MFI) by OT-I CD8+ T cells in the draining 
lymph nodes from individual mice after vehicle-treatment (closed circles) 





















































































 We next wanted to test if this inhibition of CD8+ T cell activation was 
mediated by LPA5, as we had shown in calcium mobilization assays (Figure 3.5). 
Therefore we repeated the experiment as diagrammed in Figure 3.18A, however 
we also transferred LPA5-deficient OT-I CD8+ T cells into different recipient mice 
and treated with OTP as before. In contrast to our previous findings, we were 
surprised to find that the proliferation of LPA5-deficient OT-I CD8+ T cells was 
also inhibited by OTP treatment (Figure 3.20A). This could indicate that the 
increased LPA signaling was acting on other LPA receptors on the CD8+ T cells 
and causing inhibition, however in consideration with our calcium mobilization 
assay results, this would be independent of TCR signaling. Alternatively, by 
dosing with OTP we were increasing LPA signaling to all cells, not just CD8+ T 
cells, and other cells, such as antigen-presenting cells (APC), could also be 
negatively regulated by OTP. However, we were intrigued to find that in the 
vehicle-treated controls, there was an increased accumulation of LPA5-deficient 
OT-I CD8+ T cells over LPA5-suffcient OT-I CD8+ T cells in the dLN (Figure 
3.20B). This suggested that normal levels of LPA were sufficient to inhibit LPA5-
sufficient CD8+ T cells whereas LPA5-deficient T cells were unresponsive to this 
negative regulation. In addition, this experiment was CD8+ T cell-intrinsic, as only 
the transferred OT-I CD8+ T cells lacked LPA5 and the absence of OTP dosing 
did not increase LPA signaling to endogenous cells (including APC). We decided 





Figure 3.20  OTP treatment inhibits proliferation of LPA5-
deficient OT-I; vehicle-treated LPA5–/– T cells accumulate to a 
greater extent  
(A) Representative histograms of CFSE dilution in vehicle-treated (thin 
line), OTP-treated (bold line), and unstimulated control (gray filled) LPA5-
deficient OT-I CD8+ T cells (n=1). 
(B) Number of LPA5-sufficient (black dots) and LPA5-deficient (white dots) 




TCR signaling is the critical first step in T cell activation (10). Previous 
research from our lab demonstrated that LPA inhibits B lymphocyte antigen 
receptor-mediated signaling that ultimately impairs intracellular calcium release 
from intracellular stores and indicated that this occurs via LPA5 signaling (152). 
We have found that this is also true in CD4+ and CD8+ T cells and confirmed that 
LPA5 is required for LPA inhibition in both B and T cells. Further, we demonstrate 
that inhibition of calcium mobilization is exquisitely sensitive in CD8+ T cells, with 
a dampened response with as low as 1 µM LPA, thus approximating 
physiological LPA levels (150, 177). This inhibition is ablated in LPA5-deficient T 











































indicating that a single gene copy of Lpar5 is sufficient for LPA signaling to occur 
and also possible intermediate cell surface expression of the LPA5 receptor.  
Intracellular calcium is a critical downstream effector of antigen receptor 
signaling that leads to the activation of distinct transcriptional programs important 
for T cell activation and function (166, 167). As LPA has a relatively short half-life, 
on the order of minutes in blood (66, 168), we used OTP, a recently developed 
LPA analog (68), to more stably induce LPA signaling. In vitro OTP treatment 
strongly reduced antigen-specific CD8+ T cell activation and proliferation to a 
relatively weak affinity peptide but was less effective against a higher affinity 
peptide, suggesting this LPA negative regulatory function may operate more 
effectively with weaker stimulation. This may serve as a safety mechanism to 
protect against autoimmunity, as weakly reactive T cells may be cross-reactive to 
self-tissue and LPA signaling could function to inhibit these cells from becoming 
activated and inducing damage to the host. 
We next questioned if LPA signaling also had an inhibitory effect on the 
function of in vitro-generated CD8+ T effector cells. We found that OTP treatment 
caused a slight decrease in effector cytokine generation and in cytolytic ability in 
response to SIINFEKL stimulation. We were unable to induce cytokine 
generation to G4 peptide stimulation and although others had measured OT-I 
CD8+ T cell killing of 20-40% of EL4 targets pulsed with 1 µM G4 peptide (159), 
we were unable to achieve killing with the same experimental parameters. 
However to provide optimal conditions for OTP treatment, BSA was used instead 
of FBS as the media additive, therefore the effector function was likely dampened. 
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The ability of G4 to activate naïve OT-I CD8+ T cells but not stimulate effector 
function may indicate that the affinity threshold for cytotoxic function is higher 
than that required for activation and proliferation. However we cannot exclude 
that in contrast to the activation studies, EL4 cells were used as the APC for the 
effector function studies and they may have diminished antigen presentation 
abilities as compared to primary APC (159, 178, 179).  
 By transfer of peptide-pulsed BMDC, we wanted to test the results of the 
in vitro experiments by comparing LPA inhibition of activation and proliferation to 
different affinity peptides. We questioned if we would see a greater inhibition of 
proliferation by OTP treatment if we stimulated OT-I CD8+ T cells with the lower 
affinity peptide, G4, as we had observed more potent inhibition by LPA signaling 
to G4 over SIINFEKL in vitro. However in contrast to the results of the in vitro 
experiments, we were unable to achieve OT-I CD8+ T cell activation to G4-BMDC 
in vivo. We conducted various experiments testing different peptide pulse and 
LPS maturation variables but were unable to achieve activation of transferred 
OT-I to G4-BMDC in vivo, similar to another researcher (Matt Burchill, personal 
communication). This indicated to us that G4 may not be a physiologically 
relevant peptide to stimulate OT-I CD8+ T cells in vivo when presented in the 
context of BMDC. Although other researchers have been able to activate 
transferred OT-I CD8+ T cells to lower affinity peptides, this occurred with the use 
of Listeria monocytogenes (Lm) modified to express different OT-I peptides (23), 
which results in a more robust, systemic infection and activation of T cells than 
activation from peptide-loaded dendritic cells which induces a transient presence 
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of antigen (176). Regardless, we were able to more potently inhibit activation to 
SIINFEKL peptide in vivo with OTP administration than what we observed with in 
vitro stimulation with SIINFEKL peptide, therefore we estimate that the strength 
of activation with SIINFEKL peptide is diminished in vivo. However we cannot 
exclude the possibility that the effective dose of OTP may have been greater in 
vivo than in culture. Taken together, we conclude that LPA signaling is capable of 
inhibiting TCR signaling, which results in reduced activation and proliferation both 
in vitro and in vivo. 
 Although peptide loading was not affected by OTP treatment, other cells 
that influence T cell activation could have been affected by OTP treatment, such 
as APC that engulfed the transferred SIINFEKL-BMDC or CD4+ T helper cells. 
We also cannot exclude the fact that transferred LPA5-deficient CD8+ T cells may 
have been directly inhibited by OTP treatment in an LPA5-independent manner, 
however this is less likely as our calcium data suggest that this inhibition does 
not affect activation in the absence of LPA5.  
 From these studies, we had preliminary data to suggest that endogenous 
levels of LPA inhibited normal CD8+ T cell activation, whereas LPA5-deficient 
CD8+ T cells featured a greater expansion in response to stimulation. Therefore, 
we wanted to further test how CD8+ T cells are affected by the absence of LPA5 
signaling. By using LPA5-deficient mice in the next chapter, we addressed this 
question and additionally, focused the effect of LPA signaling to CD8+ T cells 





 CHAPTER IV 
 
LPA5-DEFICIENT CD8+ T CELLS EXHIBIT ENHANCED IMMUNE 




In the previous chapter, we demonstrated that increased LPA signaling via 
LPA5 inhibited the CD8+ T cell immune response. This is significant as LPA has 
received considerable attention for its association with cancer and is produced by 
a number of different malignant cell types (84-87). The increased production of 
LPA has been shown to enhance tumor progression (116-118) by stimulating 
migration, survival, metastases, angiogenesis, drug resistance, and proliferation 
of cancer cells (119-125). One mechanism of increased LPA production is by 
upregulation of the enzyme that produces LPA, autotaxin (ATX), resulting in LPA 
concentrations up to 10 µM in individuals with certain tumors (84-87, 124).  
Various studies in mouse models have demonstrated that the immune 
system is able to identify and specifically react to tumor cells (33-35). This cancer 
immunosurveillance is chiefly mediated by tumor-specific cytotoxic CD8+ T cells 
that eliminate tumor cells expressing tumor antigens. The presence of tumor-
infiltrating T cells, and CD8+ T cells in particular, have been shown to be 
important for tumor rejection (36, 37). However multiple inhibitory mechanisms 
within the tumor microenvironment have been described that impede tumor 
rejection by T cells (39, 40) including low affinity reactivity for these tumor 
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antigens (44-47). 
In this chapter, we show that LPA5-deficient CD8+ T cells exhibit enhanced 
proliferation and accumulation in response to peptide stimulation. We further 
demonstrate that in the absence of LPA5, tumor-specific CD8+ T cells are more 
efficient in controlling tumor progression and we examine the mechanism of this 
enhanced control. Finally, we discuss our findings as the first report of 
lysophospholipid-mediated protection of tumor from adaptive immunity and LPA5 
as a potential target for cancer treatment. 
 
Results 
Characterization of LPA5-deficient mice 
 Although we had used the LPA5-deficient mice to confirm the dependence 
of LPA inhibition in the previous chapter, we wanted to further characterize these 
mice before use in activation studies as LPA5-deficient mice had not been 
described in the literature. LPA5-deficient mice were generated at Lexicon 
Pharmaceuticals on a mixed 129/SvEvBrd and C57BL/6 background, thus we 
used gender-matched littermates as controls as we backcrossed the strain to 
C57BL/6. We found that LPA5–/– mice were phenotypically unremarkable as 
compared to wild-type littermates, and heterozygous crosses resulted in 
Mendelian ratios of pups (Figure 2.1D). Comparison of LPA5+/+ and LPA5–/– mice 
revealed comparable numbers and frequencies of splenic B and T cell 
populations and CD4+ and CD8+ T cell subsets (Figure 4.1A). Importantly for 
calcium mobilization assays, the expression of surface CD3 was similar between 
LPA5+/+, LPA5+/–, and LPA5–/– CD8+ T cells, when normalized for size by gating on 
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cells of similar forward scatter (FSC slices, Figure 4.1B). Another group has 
independently generated LPA5-deficient mice and also found similar lymphocyte 





Figure 4.1  Characterization of lymphocytes in LPA5–/– mice 
(A) Proportions of B cells and T cells, and CD4+ and CD8+ T cell subsets 
in spleens of LPA5+/+ (closed circles) and LPA5–/– mice (open circles) 
(n=6/group, mean +/- SEM).  
(B) Surface expression of CD3 (right panels) was assessed in LPA5+/+ (red 
line), LPA5+/- (blue line) and LPA5–/– (green line) after gating on viable (7-




























































































































































































































































LPA5-deficient T cells show enhanced proliferation to SIINFEKL-BMDC in 
vivo 
 
We had previously shown that LPA signaling inhibited calcium mobilization 
in CD8+ T cells, however calcium mobilization in LPA5-deficient CD8+ T cells was 
not affected by LPA treatment (Figures 3.2, 3.5), confirming that LPA5 was 
required for inhibition by LPA. Thus we next wanted to determine if LPA5-
deficient CD8+ T cells were refractory to LPA inhibition of downstream biological 
events and would exhibited an enhanced response to stimulation in vivo as 
compared to wild-type CD8+ T cells. We decided to test this at physiological 
levels of LPA, as we had preliminary data that LPA5–/– OT-I CD8+ had increased 
accumulation in the dLN relative to LPA5+/+ OT-I CD8+ T cells in the absence of 
OTP treatment (Figure 3.20B). The concentration of LPA in the plasma of mice is 
approximately 1 µM (150, 168), which we have determined is sufficient to 
dampen calcium mobilization in CD8+ T cells (Figure 3.2). However, since 1 µM 
LPA does not potently inhibit calcium mobilization, we were unsure if the low 
level of inhibition observed in vitro would translate to a significant defect in 
proliferation and activation in vivo with systemic levels of LPA. To test this, we 
transferred congenically mismatched (by CD45.1 expression) LPA5-deficient or 
wild-type OT-I CD8+ T cells to C57BL/6 recipients and again stimulated by 
adoptive transfer of SIINFEKL-BMDC, in the absence of additional LPA signaling 
(Figure 4.2). By using this approach, we were able to discriminate transferred 
CD8+ T cells from endogenous CD8+ T cells by CD45.1 expression and isolate 
the deficiency of LPA5 signaling to the transferred CD8+ T cells, as the recipient 
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mice and SIINFEKL-BMDC were LPA5-sufficient. This is in contrast to the in vivo 
experiments in the previous chapter that utilized OTP treatment to increase LPA 




Figure 4.2  Schematic of adoptive transfer of OT-I CD8+ T 
cells and subsequent activation to SIINFEKL-BMDC 
CD8+ T cells were isolated from CD45-mismatched wild-type and LPA5-
deficient OT-I spleen and pooled lymph nodes and labeled with CFSE. 106 
CFSE-labeled cells were adoptively transferred intravenously to C57BL/6 
recipients a day prior to immunization. On day 0, 106 SIINFEKL-pulsed 
BMDC were transferred by subcutaneous injection to the scruff. On day 3 
after transfer of peptide-loaded BMDC, mice were sacrificed and 
transferred OT-I T cells in the draining lymph nodes were analyzed. 
 
 
We found that, as we had previously shown (Chapter 3), some of the 
transferred wild-type CD8+ OT-I T cells had proliferated in response to transfer of 
SIINFEKL-DC, although a portion of the cells had not proliferated and thus 
remained CFSEhigh (Figure 4.3A). In contrast, during the same period, LPA5-
deficient OT-I T cells featured increased cell division with fewer cells that had not 
proliferated and remained CFSEhigh (Figure 4.3A). Consistent with an increased 

















mutant OT-I CD8+ T cells had accumulated in the dLN relative to wild-type OT-I 
CD8+ T cells (Figure 4.3B). Together these data suggest that in the absence of 
negative regulation by LPA5, antigen-specific stimulation of OT-I CD8+ T cells 
trends to an increased percentage of cells that are stimulated to proliferate and, 




Figure 4.3  LPA5-deficient CD8+ T cells stimulated by 
peptide in vivo exhibit enhanced proliferation and accumulation 
Purified LPA5+/+ or LPA5–/– OT-I CD8+ T cells were CFSE labeled and 106 
cells transferred to C57BL/6 recipients, as described in Fig. 4.2.  
Recipients were injected one day later with SIINFEKL-pulsed BMDC.  3 
days after BMDC transfer, mice were sacrificed and draining lymph nodes 
harvested for analysis. 
(A) Proliferation of LPA5+/+ (thin line), LPA5–/– (bold line) or unstimulated 
(filled gray) OT-I CD8+ T cells as indicated by CFSE dilution. 
Representative of 2 independent experiments. 
(B) Number of OT-I CD8+ T cells harvested from the draining lymph nodes 
of LPA5+/+ (closed circles) and LPA5–/– (open circles) OT-I CD8+ T cell 
recipients in the absence of stimulation or 3 days after peptide stimulation. 
Cumulative of 2 independent experiments. 
 
 
Given the enhanced proliferation, we next wanted to determine if LPA5-
deficient CD8+ T cells were also more activated by analyzing expression of 
surface markers that are upregulated upon activation by flow cytometry. However, 













































cells did not exhibit enhanced activation as evaluated by expression of the 
activation markers, CD25 and CD44. Surprisingly, LPA5-deficient OT-I CD8+ T 
cells showed a delay in CD25 upregulation (Figure 4.4A). Wild-type OT-I CD8+ T 
cells upregulated CD25 and CD44 upon proliferation, starting with early divisions 
and later divisions having increased CD25 expression as compared to early 
divisions. However LPA5-deficient CD8+ T cells were able to proliferate a few 
divisions before upregulating CD25. When we analyzed the CD25 and CD44 
expression of transferred OT-I CD8+ T cells by mean fluorescent intensity (MFI), 
there was a significant decrease in population expression (Figure 4.4B), 
confirming decreased upregulation of activation markers.  
Together these data suggest that in the absence of negative regulation by 
LPA5, antigen-specific stimulation of OT-I CD8+ T cells leads to an increased 
percentage of cells that are stimulated to proliferate, resulting in higher numbers 
of antigen-specific CD8+ T cells in the dLN. However, the reduced level of 
activation was perplexing, as we would have predicted that LPA5-deficient OT-I 
CD8+ T cells would be less inhibited from activation and would thus express 
either higher levels of activation markers overall or upregulate CD25 at an earlier 
round of proliferation. Thus, we next sought to determine why there was delayed 





Figure 4.4  LPA5-deficient CD8+ T cells exhibit reduced 
activation 
Purified LPA5+/+ or LPA5–/– OT-I CD8+ T cells were CFSE labeled and 106 
cells transferred to C57BL/6 recipients, as described in Fig. 4.2.  
Recipients were injected one day later with SIINFEKL-pulsed BMDC.  
Three days after BMDC transfer, mice were sacrificed and draining lymph 
nodes harvested for analysis. 
(A) CFSE and CD25 expression of LPA5+/+ (left plot) or LPA5–/– (right plot) 
OT-I CD8+ T cells. Representative of 2 independent experiments. 
(B) The normalized MFI of OT-I CD8+ T cells 3 days after peptide 
stimulation is shown from individual LPA5+/+ (closed circles) and LPA5–/– 
(open circles) OT-I CD8+ T cell recipients for CD25 (left panel) and CD44 




LPA5-deficient CD8+ T cells do not produce nor consume IL-2 differently 
 
 In the previous section, we showed that LPA5-deficient CD8+ T cells 
exhibited enhanced proliferation but reduced CD25 expression as compared to 
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LPA5-sufficent CD8+ T cells. CD25 is the α chain of the high affinity IL-2 receptor 
trimer. The IL-2 receptor can bind IL-2 with a lower affinity when it is a dimer 
composed of the common γ chain and CD122. However when the IL-2 receptor is 
expressed as a trimer of the common γ chain, CD122, and CD25, the addition of 
CD25 increases the affinity for IL-2 by a magnitude of 10- to 100-fold. Thus, 
CD25 confers high affinity to the IL-2 receptor (173). Naïve CD8+ T cells are 
CD25– and TCR signaling induces IL-2 production, which leads to autocrine IL-2 
signaling resulting in internalization and degradation of IL-2, and increased CD25 
expression (173, 180). As we had also seen a delay of CD25 upregulation in 
LPA5-deficient CD8+ T cells (Figure 4.4A), we questioned if the lack of LPA5 
expression resulted in delayed IL-2 production or defective IL-2 receptor binding 
by IL-2.  
  To determine if LPA5-deficient CD8+ T cells produced less IL-2, we 
stimulated purified LPA5–/– and LPA5+/+ OT-I CD8+ T cells with SIINFEKL-BMDC 
in vitro, then collected supernatants and assayed for IL-2 production by ELISA. 
We found no significant difference in IL-2 production at any timepoint tested 
(Figure 4.5A). This showed that the LPA5 deficiency did not result in reduced IL-2 
production to explain the delay in CD25 expression. We also wanted to test if  
IL-2 consumption was different, as upon IL-2R binding, IL-2 is internalized and 
degraded, depleting the culture of exogenous IL-2. Thus we added IL-2 to the 
culture and measured internalization indirectly by the loss of IL-2 in the culture 
supernatant over time by IL-2 ELISA (181). Over a 3 day timecourse, we again 
did not find a difference in consumption of IL-2 by stimulated LPA5–/– and LPA5+/+ 
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OT-I CD8+ T cells (Figure 4.5B). Additionally, we did not find a difference in IL-2 
consumption in the absence of stimulation (data not shown). This indicates that 
neither IL-2 production nor consumption are different in LPA5–/– and LPA5+/+ OT-I 
CD8+ T cells in vitro. However, we also did not see a delay in CD25 upregulation 
in LPA5–/– OT-I CD8+ T cells in response to in vitro stimulation as we did in vivo 
(data not shown), which indicates differential CD25 upregulation between our in 




Figure 4.5  IL-2 production and consumption is similar by 
LPA5+/+ and LPA5–/– CD8+ OT-I T cells 
CD8+ T cells were purified from pooled splenocytes and lymph nodes from 
LPA5+/+ or LPA5–/– OT-I mice. 105 CD8+ T cells were cultured at a 2:1 
(“DC”, squares) or 10:1 (“low DC”, circles) ratio with SIINFEKL-BMDC in 
the absence (A) or presence (B) of 15 ng/mL rmIL-2. Supernatants were 
collected at the indicated timepoints and assayed for IL-2 by ELISA. 
Cumulative of 2 independent experiments. 
 
 
Transfer of LPA5–/– OT-I CD8+ T cells controls tumor growth in vivo 
Our data thus far show that LPA signaling via LPA5 on CD8+ T cells 
impairs T cell activation and proliferation. Strikingly, a number of different tumor 
and malignant cell types have been reported to produce elevated levels of LPA 
that, in turn, promotes survival, growth and tumorigenesis (84-87). However the 








































has not been addressed. Our findings suggest that this increased LPA production 
may contribute to the immune suppression observed in the tumor 
microenvironment. Thus, we next asked if LPA5-deficient tumor-specific CD8+ T 
cells would be unaffected by the increased LPA concentration and thus be able 
to better control tumor progression over LPA5-sufficient CD8+ T cells.  
Autotaxin was originally isolated from the ascites fluid of a human 
melanoma (70) and the B16 C57BL/6 melanoma cell line expresses functional 
autotaxin that can convert LPC to LPA (Gabor Tigyi, personal communication). 
We elected to use a derivative of the B16 line: the B16.cOVA line expresses 
chicken ovalbumin constitutively and is thus able to present “tumor antigen” 
directly to OT-I CD8+ T cells. This allowed us to directly compare tumor-specific 
responses of LPA5-deficient versus LPA5-sufficient CD8+ T cells in the context of 
a melanoma. We decided to implant the tumor cells by subcutaneous injection, 
so that tumor progression could be tracked over time by measuring the diameter 
of the tumor. Preliminary experiments revealed that subcutaneous injection of 
B16.cOVA cells in the leg led to consistent tumor growth that was palpable and 
measurable. Thus, B16.cOVA cells were implanted in the rear leg of C57BL/6 
mice and allowed to establish for 5 days whereupon either naïve LPA5-deficient 
or LPA5-sufficient tumor-specific CD8+ T cells were transferred by intravenous 





Figure 4.6 Schematic of tumor implantation and OT-I CD8+ 
T cell adoptive transfer 
105 B16.cOVA cells were implanted s.c. in the leg of C57BL/6 recipients.  
Five days post-implantation, 0.5 x 106 LPA5+/+ or LPA5–/– tumor-specific 
(OT-I) CD8+ T cells were transferred i.v. and tumor progression evaluated 
at the specified timepoints. 
 
 
With this experimental design, we measured tumor diameter every 2 days 
to determine if the transfer of LPA5–/– tumor-specific CD8+ T cells could control 
tumor progression better than wild-type tumor-specific CD8+ T cells. We were 
excited to find that while tumors grew similarly in the absence or presence of 
wild-type tumor-specific CD8+ T cell transfer, tumor growth was abated in mice 
that received LPA5-deficient tumor-specific CD8+ T cells (Figure 4.7). Averaging 
tumor size across a treatment group revealed that while tumors were similar in 
size at the time of T cell transfer, a significant reduction in tumor size was 
observed at 6 and 8 days post-transfer of LPA5–/– tumor-specific CD8+ T cells 
compared to wild-type T cells (Figure 4.7B). These findings indicate that transfer 
















Figure 4.7 LPA5-deficient OT-I CD8+ T cells control 
B16.cOVA growth 
(A) B16.cOVA cells were implanted and tumor size is shown for individual 
mice at the indicated timepoints in the absence of CD8+ T cell transfer 
(gray circles; n=9) or after adoptive transfer of LPA5+/+ (black circles, n=10) 
or LPA5–/– (open, n=11) OT-I CD8+ T cells.  Data are cumulative of 3 
independent experiments. 
(B) Average combined tumor burden of Fig. 4.7A. Data are cumulative of 3 
independent experiments (mean +/- SEM). Statistical significance was 




When we excised these tumors, we found that the tumor diameter 
measurements correlated with less vascularized, more compact tumors (Figure 
4.8A). In contrast, tumors harvested from LPA5+/+ tumor-specific CD8+ T cell 
recipients and control mice were often penetrant into the local tissue and well 
vascularized. We did not observe metastases in the lungs by visual inspection in 
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cells to better control tumor progression compared to wild-type CD8+ T cells was 
further shown by the significantly smaller tumors harvested from mice that 
received LPA5-deficient tumor-specific CD8+ T cells as compared to the other 
treatment groups (Figure 4.8B). Thus, these data show that tumor growth is 





Figure 4.8 Transfer of LPA5-deficient CD8+ T cells results in 
smaller tumors 
(A) Representative tumors in situ and ex vivo from C57BL/6 mice after 8 
days in the absence of T cell transfer or post-adoptive transfer of LPA5+/+ 
or LPA5–/– tumor-specific CD8+ T cells. 
(B) Tumor mass at time of sacrifice after adoptive transfer of LPA5+/+ OT-I 
(black, n=10), LPA5–/– OT-I (white, n=11) or untreated controls (gray, n=9).  

























































Single transfer of LPA5-deficient OT-I T cells is not sufficient to ablate B16.cOVA 
tumor 
 
 Our initial results showed that injection of LPA5–/– tumor-specific CD8+ T 
cells could control tumor growth within a week of transfer and we next questioned 
if these T cells could reject the tumor completely. Therefore, we repeated the 
experiment (Figure 4.6) except we continued the experiment beyond 8 days as a 
survival study and euthanized mice once the tumor reached a diameter greater 
than 1 cm. We found that in this experiment, transfer of neither LPA5–/– or wild-
type tumor-specific CD8+ T cells conferred long-term protection from tumor 
burden (Figure 4.9A). Mice were euthanized due to tumor burden at similar 
timepoints as compared to mice that did not receive OT-I T cells. In one of the 
two experiments, excised tumors were analyzed for the presence of transferred 
OT-I CD8+ T cells within the tumor, dLN, and ndLN. We did not detect remaining 
OT-I CD8+ T cells in mice that were euthanized at later timepoints, regardless of 
LPA5 expression (data not shown). This indicated to us that a single transfer of 
naïve T cells may be insufficient to clear a tumor and serial transfers may induce 
better tumor regression. This has been shown in clinical trials where transfer of 
tumor-specific T cell lines to patients resulted in detectable levels of T cells for 
only 14 days and only with IL-2 infusions to boost T cell survival (182). 
We questioned if we could achieve better protection if we transferred 
CD8+ T cells on the same day as tumor implantation, rather than allowing the 
tumor to establish before transferring CD8+ T cells. In this preliminary experiment, 
we did see extended protection with OT-I transfer, however there was no 
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appreciable difference between the LPA5–/– and LPA5+/+ OT-I recipients (Figure 
4.9B). The survival curves of the OT-I recipients were influenced by one mouse 
per group that survived beyond 30 days post-T cell transfer (Figure 4.9C). 
Interestingly, the LPA5-sufficient OT-I CD8+ T cell recipient had a measurable 
tumor that remained at a consistent size for approximately 10 days, was 
undetectable on days 21-25, then resurfaced on day 27 and ultimately grew 
greater than 1 cm. In contrast, one LPA5-deficient OT-I CD8+ T cell recipient did 
not exhibit a measurable tumor until 31 days post-transfer of T cells. Although 
these data represent one independent experiment, they suggest that transfer of 
OT-I CD8+ T cells simultaneous to the tumor allows better control of tumor 




Figure 4.9 A single transfer of LPA5-deficient CD8+ T cells 
is insufficient to protect mice from B16.cOVA tumors 
(A) Survival curve after adoptive transfer of LPA5+/+ OT-I (black, n=6), 
LPA5–/– OT-I (white, n=6) or untreated controls (gray, n=5) 5 days after 
tumor transfer. Data are cumulative of 2 independent experiments (p=ns, 
Mantel-Cox log rank test). 
(B) Survival curve after adoptive transfer of LPA5+/+ OT-I (black, n=3), 
LPA5–/– OT-I (white, n=3) or untreated controls (gray, n=3) simultaneous to 
tumor transfer. 1 experiment (p=ns, Mantel-Cox log rank test). 
(C) Tumor size is shown at the indicated timepoints for individual mice in 
Fig. 4.9B.   
 

















































LPA5–/– OT-I CD8+ T cells accumulate within the tumor  
 Thus far, we have shown that LPA5-deficient CD8+ T cells control 
established tumor progression better than LPA5-sufficient CD8+ T cells in a short-
term experiment. We next questioned if this enhanced tumor control was due to 
increased proliferation and accumulation of transferred LPA5–/– tumor-specific T 
cells, as we had observed in previous experiments.  
 We first performed various experiments to examine T cell proliferation 
within the tumor and dLN at 3, 5, and 8 days post-T cell transfer, by transferring 
purified CFSE-labeled OT-I CD8+ T cells to tumor-bearing recipients, as before 
described (Figure 4.6). From these studies, we found that there was a trend of 
increased proliferation of LPA5-deficient OT-I CD8+ T cells relative to LPA5-
sufficient OT-I CD8+ T cells in the tumor and dLN by 3 days post-transfer, though 
this difference was not significant (Figure 4.10). By day 5 post-transfer, roughly 
the same number of LPA5–/– and LPA5+/+ OT-I CD8+ T cells had proliferated in the 
tumor and dLN (Figure 4.10) and by day 8, both populations of OT-I CD8+ T cells 
had divided completely in the tumor and were CFSE negative (data not shown). 
This suggested that perhaps LPA5–/– OT-I CD8+ T cells were capable of more 
rapid proliferation after transfer to tumor-bearing recipients, however by day 5, 





Figure 4.10 Proliferation of LPA5-deficient OT-I T cells 
trends to be increased at day 3  
105 B16.cOVA cells were implanted s.c. in the leg of C57BL/6 recipients 
as in Fig. 4.6.  Five days post-implantation, 0.5 x 106 CD45.1+ LPA5+/+ 
(closed circles) or LPA5–/– (open circles) OT-I CD8+ T cells were purified, 
CFSE labeled, and transferred by intravenous injection to tumor-bearing 
recipients. Mice were euthanized at 3 or 5 days post-transfer and tumors 
were assessed for proliferation of OT-I CD8+ T cells by CFSE dilution. 
(A) Proliferation of OT-I T cells in the tumor at 3 (left panel, p=0.3) or 5 
(right panel, p=0.2) days post-transfer. Data are cumulative of 2 
independent experiments. 
(B) Proliferation of OT-I T cells in the dLN at 3 (left panel, p=0.2) or 5 (right 



















































 We next assessed if this modest difference in proliferation would result in 
differential accumulation of OT-I CD8+ T cells in the tumor. When we assessed 
OT-I CD8+ T cell accumulation as a proportion of infiltrating CD8+ T cells, we 
found a slight increased presence of LPA5-deficient OT-I CD8+ T cells at earlier 
timepoints (d3, d5) but not at 8 days post-transfer (Figure 4.11A). When we 
quantified the concentration of OT-I CD8+ T cells per gram of tumor, we again 
found a trend of increased number of LPA-deficient OT-I CD8+ T cells in the 
tumor at 3 and 5 (p=0.15) days post-transfer (Figure 4.11B). However in contrast, 
by day 8 the concentration of LPA5-deficient OT-I CD8+ T cells was roughly 
equivalent to the concentration of LPA5-sufficient OT-I CD8+ T cells in the tumor, 
though LPA5–/– OT-I CD8+ T cells trended to be a lesser proportion of the 
infiltrating CD8+ T cells. Taken together, this indicates that although transferred 
tumor-specific LPA5+/+ and LPA5–/– CD8+ T cells are present at similar 
concentrations by day 8, transferred LPA5–/– tumor-specific CD8+ T cells 
represent a smaller fraction of the total infiltrating population of CD8+ T cells. 
Thus, an increase of endogenous CD8+ T cells in the tumor is also observed in 
LPA5–/– OT-I CD8+ T cells recipients, resulting in a significantly increased 
percentage of total CD8+ cells within the tumor (Figure 4.11C). This suggests that 
the presence of transferred LPA5-deficient tumor-specific T cells alters the tumor 
microenvironment to allow infiltration of endogenous CD8+ T cells. This 
phenomenon could be further probed by examination of the endogenous CD8+ T 
cells within the tumor for tumor specificity and anti-tumor function by cytokine 
staining, to determine the potential contribution of host CD8+ T cells to anti-tumor 
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immunity. In addition, the contribution of the transferred OT-I CD8+ T cells versus 
the endogenous T cell response could be further probed by transfer of OT-I CD8+ 
T cells into tumor-bearing T cell-deficient or TCR non-specific recipients, to 
prevent an endogenous anti-tumor CD8+ T cell response. However, we already 
know that any potential contribution of endogenous CD8+ cells is insufficient to 
clear the tumor, even when combined with a single transfer of LPA5–/– OT-I CD8+ 
T cells (Figure 4.9). 
When we examined the activation status of the transferred OT-I CD8+ T 
cells, we found that CD25 was not upregulated and CD44 upregulation was only 
modestly detectable with no difference between LPA5+/+ and LPA5–/– OT-I CD8+ T 
cells in the tumor and the dLN by day 5 (data not shown). We returned to in vitro 
experiments to compare additional activation markers in LPA5-deficient CD8+ T 
cells as compared to wild-type CD8+ T cells. To determine differences in 
activation and homing marker expression in vitro, we pulsed C57BL/6 
splenocytes with SIINFEKL and used them to stimulate purified LPA5–/– or 
LPA5+/+ OT-I CD8+ T cells in vitro. In a preliminary experiment, we did not see a 
difference in PD-1, CCR7, nor CD127 expression between the two groups (data 
not shown), similar to previous findings (149). We thus next questioned if the 







Figure 4.11 Trend of slightly increased concentration of 
LPA5-deficient OT-I CD8+ T cells in the tumor at 3 and 5 days 
post-transfer 
C57BL/6 recipients were implanted s.c. in the leg with 105 B16.cOVA cells 
as in Fig. 4.6.  Data shown are from LPA5+/+ (closed circles) or LPA5–/– 
(open circles) OT-I CD8+ T cell recipients.  
(A) Percent OT-I T cells of CD8+ T cells in the tumor was assessed at 3 
(left panel, p=1.0), 5 (center panel, p=0.3), or 8 (right panel, p=0.09) days 
post-transfer. Data are cumulative of 4 (d3) or 2 (d5, d8) independent 
experiments (mean +/- SEM). 
(B) Number of OT-I per gram of tumor was assessed at 3 (left panel, 
p=0.4), 5 (center panel, p=0.15), or 8 (right panel, p=0.9) days post-
transfer. Data are cumulative of 3 (d3) or 2 (d5, d8) independent 
experiments (mean +/- SEM). 
(C) Percentage of tumor cells that are CD8+ in tumor-bearing recipients 
that received no OT-I T cells (gray circles), or 0.5 x 106 CD45.1+ LPA5+/+ 
(closed circles) or LPA5–/– (open circles) OT-I CD8+ T cells. Cumulative of 































































































































































LPA5–/– T cells kill target cells and produce intracellular cytokines similarly to wild-
type T cells 
 
 Although we were unable to detect a difference in activation, we next 
asked if LPA5–/– CD8+ T cells were more adept at generating an effector 
response. We first addressed this question by conducting an in vivo cytotoxicity 
assay, by transfer of control and SIINFEKL-pulsed target cells into tumor bearing 
recipients that had received either LPA5-deficient or –sufficient OT-I CD8+ T cells 
(Figure 4.12A). Target cells were distinguished from host cells by congenic 
marker expression (CD45.1) and from each other by CFSE staining (CFSEhigh 
versus CFSElow). Killing was assessed by the loss of SIINFEKL-pulsed target 
cells relative to control cells that did not express SIINFEKL. Having observed 
smaller tumors in LPA5-deficient OT-I CD8+ T cells recipients, we predicted that 
LPA5–/– OT-I CD8+ T cells recipients would feature a higher level of killing of 
target cells, however we were surprised to see that there was no difference in 
killing, in either the tumor (Figure 4.12C) or the dLN (Figure 4.12B). A higher 
proportion of SIINFEKL-pulsed targets were killed in the dLN, likely due to the 
increased number of CD8+ T cells in the dLN. This shows that SIINFEKL-labeled 
target cells are equally cleared in tumor-bearing LPA5+/+ and LPA5–/– OT-I CD8+ T 







Figure 4.12 Killing ability is similar in the dLN and tumor of  
LPA5–/– and LPA5+/+ OT-I T cell recipients 5 days after T cell 
transfer 
(A) Schematic of in vivo cytotoxicity assay. C57BL/6 recipients were 
implanted s.c. in the leg with 0.5 x 105 B16.cOVA cells.  Five days post-
implantation, 106 CFSE-labeled LPA5+/+ or LPA5–/– OT-I CD8+ T cells were 
transferred i.v. C57BL/6 splenocytes were divided to two populations and 
one population was labeled CFSEhigh and pulsed with SIINFEKL and the 
second population was labeled CFSElow and not pulsed with peptide. The 
CFSEhigh and CFSElow cells were combined at a 1:1 ratio and injected i.v. 
1 day before harvest. 
(B-C) The ability of LPA5+/+ (upper row) and LPA5–/– OT-I (lower row) to kill 
target cells (CFSEhigh) is shown in the dLN (B) and tumor (C). Each 
histogram represents one C57BL/6 tumor-bearing recipient and control 
histogram is from a naïve C57BL/6 recipient. Representative of 2 
experiments. 
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Although we were unable to detect a difference in the killing ability of 
LPA5-deficient and LPA5-sufficient OT-I CD8+ T cells in vivo, we wanted to test if 
the effector cytokine generation profiles were affected by signaling via LPA5. To 
address this question, we pulsed purified OT-I CD8+ T cells and C57BL/6 
splenocytes with SIINFEKL peptide and then removed unbound peptide and 
cultured the cells for 3 days. We then further cultured cells with brefeldin A for 5 
hours to induce intracellular cytokine accumulation. By this method, we did not 
detect a significant difference in intracellular TNFα production between LPA5-
deficient and LPA5-sufficient OT-I CD8+ T cells but interestingly, found a slight 
decrease in intracellular IFNγ staining, both by percentage and MFI of the entire 
CD8+ OT-I CD8+ T cell population (Figure 4.13). Although we would have 
predicted that LPA5-deficient CD8+ T cells would produce a greater level of 
effector cytokines, the similarities between LPA5+/+ and LPA5–/– CD8+ cytokine 
production was congruous with our previous in vitro findings that LPA signaling 
does not potently affect IFNγ and TNFα production (Figure 3.12). Taken together 
with our findings from activation studies, this suggests that LPA inhibition may 
operate over initial antigen receptor signaling, activation, and proliferation of 
CD8+ T cells, however once CD8+ T cells are activated, the effector function is 





Figure 4.13 LPA5–/– OT-I T cells produce slightly less IFNγ  but 
equivalent TNFα as LPA5+/+ OT-I T cells 
CD8+ T cells were purified from LPA5+/+ or LPA5–/– OT-I splenocytes and 
lymph nodes, and combined at a 1:2 ratio with C57BL/6 splenocytes 
before pulse with SIINFEKL peptide. Cells were washed and plated at 2.5 
x 106 cells/mL. On day 3, cells were transferred to a round-bottom plate 
and brefeldin A was added for 5 hours. Cells were then fixed, 
permeablized, and stained for IFNγ or TNFα and were analyzed by flow 
cytometry. Data shown is from gated OT-I CD8+ T cells. 
(A-B) Representative staining of IFNγ (A) or TNFα (B) staining with % 
postitive indicated. Representative of 2 independent experiments. 
(C-D) MFI of IFNγ (A) or TNFα (B) staining of LPA5+/+ or LPA5–/– OT-I 
CD8+ T cells (n=2). 
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Conclusion  
 In the previous chapter, we found that increased LPA signaling via LPA5 
was sufficient to inhibit CD8+ T cell activation and proliferation. We acquired 
LPA5-deficient mice and found them to be phenotypically unremarkable with 
similar lymphocyte populations to wild-type littermates. Two other groups have 
recently published studies with independently generated LPA5–/– mice (115, 183) 
and Lin et al. also reported similar lymphocyte populations. When we compared 
the activation of LPA5–/– CD8+ T cells with wild-type CD8+ T cells by calcium 
mobilization assay, we found that LPA5–/– CD8+ T cells were not inhibited by LPA 
(Figure 3.5). Thus we hypothesized that as we had shown that increased LPA 
signaling inhibited the CD8+ T cell response via LPA5, ablating signaling to that 
receptor would negate that inhibition and allow an enhanced CD8+ T cell 
response.  
 To test this hypothesis, we transferred LPA5-deficient or –sufficient OT-I 
CD8+ T cells into C57BL/6 mice and stimulated the transferred cells by 
subsequent transfer of SIINFEKL-BMDC. We were initially unsure if we would 
see a significant difference in the CD8+ T cell response, as we were not 
increasing the concentration of LPA by OTP injection and we were stimulating 
OT-I CD8+ T cells with the high affinity peptide, SIINFEKL, which we had 
previously shown to be less affected by LPA signaling. However we found that as 
predicted from in vitro experiments, LPA5–/– CD8+ T cells proliferated and 
accumulated to a greater degree than their wild-type counterparts. This indicates 
that the low concentration of LPA found in the mouse (1 µM in plasma) is 
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sufficient to dampen, though not ablate proliferation if OT-I CD8+ T cells in 
response to SIINFEKL peptide stimulation. However the concentration of LPA in 
lymph nodes is unknown and we cannot exclude the possibility that transfer of 
mature SIINFEKL-BMDC may alter the concentration of LPA.  
 We were surprised to observe that activation marker upregulation was not 
increased in LPA5-deficient OT-I CD8+ T cells but in contrast, was delayed in 
comparison to wild-type OT-I CD8+ T cells. Further, it was curious that LPA5–/– 
OT-I T cells could proliferate for a few rounds of division in the absence of 
expression of the high affinity chain of the IL-2 receptor, CD25 (Figure 4.4). We 
tested if IL-2 production or consumption was different in vitro but we could not 
find any dissimilarities (Figure 4.6). However when we examined the CD8+ T 
cells in this experiment, we also did not see a difference in CD25 expression, 
which indicated that the in vitro experiment did not recapitulate what we had 
previously observed in vivo. Thus the reason for the reduced CD25 expression 
observed in LPA5–/– OT-I T cells in response to SIINFEKL-BMDC stimulation 
remains to be elucidated. 
 With the finding that LPA5-deficient CD8+ T cells featured enhanced 
proliferation and accumulation, we wanted to test how LPA signaling would affect 
the CD8+ T cell response to tumor. It has been well reported that a variety of 
tumor and malignant cell types produce elevated levels of LPA that promotes 
tumorigenesis by enhancing survival, growth, and angiogenesis (84-87). As B16 
melanomas express functional ATX, we tested how LPA5 signaling by OT-I CD8+ 
T cells influenced control of tumor growth of SIINFEKL-expressing melanoma, 
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with the prediction that LPA5–/– OT-I CD8+ T cells would have better anti-tumor 
capabilities in the presence of pathogenic levels of LPA. 
To test this, we implanted B16.cOVA cells s.c. in mice and allowed the 
tumor to establish for five days before transfer of naïve LPA5–/– or LPA5+/+ OT-I 
CD8+ T cells. As we had previously shown that LPA inhibition was more potent 
with a less robust stimulation, we were unsure if we would detect a difference 
with LPA5–/– OT-I CD8+ T cells in response to a high affinity peptide with tumor 
stimulation. Impressively, tumor-specific CD8+ T cells transferred to recipients 
with established subcutaneous melanoma tumors were able to significantly 
control tumor growth when unable to signal via the LPA5 receptor. This resulted 
in much smaller tumors when excised that trended to have a higher 
concentration of OT-I CD8+ T cells. This indicates that with stimulation to a high 
affinity antigen in the context of a tumor, LPA signaling is potent enough to 
impact the CD8+ anti-tumor response, and ablating LPA5 signaling allows greater 
T cell accumulation and control of tumor progression.  
When we examined LPA5+/+ and LPA5–/– OT-I CD8+ T cells, we did not find 
significant differences in activation or effector cytokine production. However we 
did see a trend of increased proliferation and concentration of LPA5-deficient  
OT-I CD8+ T cells in the tumor at earlier timepoints. This could indicate that 
tumor-specific CD8+ T cells lacking LPA5 are able to more quickly expand and 
control tumor growth than wild-type OT-I CD8+ T cells. 
While we observed a decrease in tumor growth with transfer of LPA5–/– 
OT-I T cells, we did not see an effect with transfer of wild-type OT-I T cells. 
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Although we were surprised that wild-type OT-I CD8+ T cells did not affect tumor 
growth, published studies showing a decrease in B16.cOVA tumor burden with 
wild-type OT-I T cell transfer utilized in vitro generated effector cells and/or 
transferred OT-I T cells earlier than 5 days post-transfer of tumor (184, 185). 
When we transferred OT-I CD8+ T cells on the same day as tumor, we achieved 
similar tumor control by both LPA5+/+ and LPA5–/– OT-I CD8+ T cells. This 
indicates that the timing and activation state of transferred CD8+ T cells can have 
a profound effect of the outcome of this experiment. As our initial experimental 
design more closely mimics a tumor therapeutic strategy, this suggests that 
dampening of LPA5 signaling on CD8+ T cells could have a beneficial anti-tumor 
effect with established tumors. Consistent with these findings, our collaborators 
have found that B16 melanomas metastasize in wild-type mice, but not in LPA5–/– 
mice (Gabor Tigyi, personal communication). Although in their experiments the 
LPA5 deficiency is not restricted to CD8+ T cells, the correlation with our results is 













A model for LPA inhibition of CD8+ T cells 
 Adaptive immunity is the specialized arm of the immune response that 
locates, targets, and facilitates the removal of foreign invaders in a specific 
manner. CD8+ T cells in particular are important for their cytotoxic ability to 
identify and kill infected and altered self cells, such as cancer cells. With such a 
powerful subset of cells, a variety of mechanisms exist to modulate the T cell 
response and temper activation of T cells to minimize or prevent damage to the 
host. It has been well documented that the lysophospholipid, LPA, has a variety 
of effects on different cell types and that LPA receptors are present on immune 
cells (57, 87), however how LPA affects the adaptive immune response has not 
been thoroughly addressed. We have previously shown that LPA functions to 
inhibit B cell activation and antibody production. Given the signaling similarities 
between B and T cells, we questioned if LPA would also inhibit the CD8+ T cell 
response, with the hypothesis that increased LPA signaling would decrease 
CD8+ T cell activation and effector function. Finally, we wanted to test if this 
inhibition would affect an immune response to a known condition that increases 
LPA concentrations within individuals; cancer.  
In chapter III, we demonstrate that, similar to B cells, LPA potently 
dampens T cell signaling via inhibition of intracellular calcium release and LPA5. 
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We questioned if this defect in TCR signaling would translate to decreased 
activation and proliferation in response to stimulation. Initial experiments 
revealed that LPA inhibition was most potent with sub-optimal levels of anti-CD3 
stimulation, which activates T cells by cross-linking the CD3 subunit of the T cell 
signaling complex. To use a more physiological stimulus we elected to use 
peptides to stimulate CD8+ T cells from OT-I mice, a well-characterized TCR 
transgenic model. By use of this model, we used different affinity peptides to 
show that LPA more potently inhibited stimulation by a lower affinity peptide (G4) 
than a high affinity peptide (SIINFEKL) (Figures 3.8, 3.9, 3.11), which coincides 
with a previous finding of increased impact of LPA induction of IL-13 production 
by CD4+ T cells with sub-optimal stimulation (147). Considering these findings, 
we propose a model where the potency of LPA inhibition is dependent on the 
strength of stimulation (Figure 5.1). A strongly activated CD8+ T cell, such as an 
OT-I CD8+ T cell activated by SIINFEKL peptide, will proliferate and accumulate 
robustly in the absence of LPA. In the presence of LPA, CD8+ T cell proliferation 
is dampened but not ablated, resulting in decreased accumulation. In contrast, a 
weaker activation, such as OT-I CD8+ T cells activated by SIIGFEKL (G4) 
peptide, will result in reduced proliferation as compared to activation by a 
strongly activating peptide. In the presence of LPA, proliferation of CD8+ T cells 
as a result of weaker activation is ablated, preventing accumulation and 





Figure 5.1 A model for LPA regulation of CD8+ T cell activation to 
different affinity peptides 
We propose that when a naïve CD8+ T cell is activated via strong TCR signal, 
such as a high affinity peptide, proliferation is slightly dampened by the presence 
of LPA. In contrast, when a naïve CD8+ T cell is activated by a weaker TCR 
signal, LPA signaling potently inhibits proliferation. 
 
 
This concept of reduced influence of a TCR co-receptor with strong TCR 
stimulation is not entirely new, as it has been shown that strong TCR stimulation 
can negate the need for positive co-stimulation by the canonical T cell co-
receptor, CD28, whereas weak TCR stimulation requires CD28 signaling for T 
cell activation (13, 14). However in the case of inhibitory receptors, increased 
strength of TCR signaling does not always equate with reduced inhibition, as 
increased TCR signaling has been shown to increase the accumulation of the T 








receiving stronger stimuli are more sensitive to CTLA-4 signaling (186). By this 
mechanism, strongly activated T cells are also more susceptible to CTLA-4-
mediated attenuation of the T cell response and this provides a rapid method of 
halting the T cell response. In contrast, we have found that strongly activated T 
cells are relatively resistant to LPA inhibition. This presents a novel pathway by 
which signaling by a lysophospholipid is an inhibitory rheostat for T cell activation 
and suggests that in contrast to CTLA-4 that is upregulated as an “emergency 
brake” to quell T cell responses, LPA signaling functions to temper responses 
starting from initiation of T cell signaling. This signaling could prevent weakly 
activated T cells, possibly from inappropriate autoreactive activation by self 
tissue, from a robust proliferative response. In support of this theory, 
collaborators have found exacerbated disease development in LPA5–/– mice in an 
induced autoimmune model (Tamas Oravecz, personal communication). As 
earlier described, extracellular levels of LPA are tightly regulated, and this could 
indicate a delicate system of immune control that has evolved to prevent 
unwanted immune responses. 
 CTLA-4–/– mice feature a lymphoproliferative disorder characterized by T 
cell proliferation and infiltration into non-lymphoid tissues, and become moribund 
by 3-4 weeks of age (187-189). We have not found evidence of this in LPA5–/– 
mice within this timeframe. This could indicate that in contrast to CTLA-4, 
inhibition via LPA5 is not important for regulation of T cell homeostasis. In 
consideration of our calcium mobilization assays demonstrating that LPA 
treatment in the absence of antigen receptor stimulation has no effect on calcium 
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mobilization, inhibition through LPA5 may only occur in conjunction with antigen 
receptor signaling. This would indicate that LPA signaling has little influence on 
the status of resting T cells but functions to curb the T cell response during an 
immune event. However TCR signaling does occur during thymic development, 
as T cells are tested for self-reactivity, thus it would be interesting to determine 
LPA5 expression on developing thymocytes and if LPA signaling affects T cell 
development. If LPA5 is present on thymocytes and functions similarly to dampen 
TCR signaling, we would predict that LPA5–/– mice would feature a different T cell 
repertoire. Increased LPA signaling during thymic development would dampen 
TCR signaling on potentially autoreactive T cells, allowing these autoreactive T 
cells to enter the periphery and possibly induce autoimmunity. 
This model (Figure 5.1) is particularly interesting when considered in the 
context of cancer. High affinity tumor-specific T cells have by definition a degree 
of self-reactivity since they are responding to modified self tissue and thus have 
been reported to be deleted during thymic education. Therefore T cells specific 
for tumor antigens typically display low affinity for these ‘self tumor antigens’ (44-
47). Our findings would indicate that LPA signaling would thus have a more 
potent effect on these tumor-specific T cells that are stimulated by only lower 
affinity antigens. As LPA production appears to be a hallmark for a variety of 
cancer cell types (84-87), this would provide an additional mechanism to explain 
why it is difficult to generate an effective immune response to tumor. 
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LPA signaling in CD8+ T cells in vivo: implications for enhancing the 
CD8+ T cell response 
We next tested if the in vitro findings of LPA inhibition of CD8+ T cell 
activation would translate to in vivo experiments. We continued to use the OT-I 
model by transferring purified OT-I CD8+ T cells into C57BL/6 mice and 
stimulating these cells with transfer of peptide-pulsed bone marrow-derived 
dendritic cells (BMDC). By use of congenic markers, we were able to distinguish 
transferred OT-I T cells from the endogenous T cells and determine the effects of 
increased LPA signaling by treating with a stable LPA analog, OTP. By this 
method, we were surprised that we were unable to achieve activation to the 
lower affinity G4 peptide in the context of BMDC, in contrast to our in vitro results. 
In a similarly designed study, Zehn et al. achieved in vivo activation of transferred 
OT-I to a variety of peptides by the generation of recombinant Listeria 
monocytogenes (Lm) strains containing SIINFEKL or altered SIINFEKL-derived 
peptides (23). The panel of peptides included lower affinity peptides as low as 
680-fold less potent over SIINFEKL (SIIVFEKL) and yet they observed a degree 
of expansion to each lower affinity peptide tested. We found that in contrast to 
Lm-OVA peptide infection that induced activation of T cells in various lymphoid 
organs, our SIINFEKL-BMDC transfer resulted in localized activation isolated to 
the draining lymph node. This limited activation by peptide-BMDC transfer has 
been exploited by others as a transient introduction of antigen (176). Therefore 
we estimate that the peptide presentation “vector” of BMDC was insufficient to 
activate transferred OT-I CD8+ T cells to lower affinity peptides but Lm is a 
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stronger vector that can be used to compare lower affinity peptides in vivo. We 
predict that immunization with different Lm-OVA peptide strains would reveal 
increased inhibition by LPA signaling over weaker affinity peptide stimulation. 
However we also expect that immunization with Lm-OVA peptides would shift 
activation such that a moderately activating peptide when presented by BMDC 
would be strongly activating within the Lm construct. As a result, a lower affinity 
Lm-peptide would induce proliferation in transferred OT-I CD8+ T cells and this 
proliferation may be ablated or at least strongly inhibited by OTP treatment, as 
we observed in vitro with G4 peptide stimulation (Figure 3.8). 
In chapter IV, we explored how the CD8+ T cell response is affected by 
genetic deletion of LPA5. We predicted that without the inhibition via LPA5, these 
T cells would exhibit an enhanced response to stimulation. We repeated the 
experimental design from the in vivo experiments in chapter III, except that the 
transferred OT-I CD8+ T cells were either LPA5+/+ or LPA5–/–. In contrast to the 
experiments in chapter III when we increased LPA signaling to all cells by OTP 
administration, we relied on endogenous sources of LPA, which have been 
reported to be in the high nanomolar to low micromolar range (63, 117, 163). In 
addition, we focused the effect of LPA signaling to the transferred OT-I CD8+ T 
cells by modulating expression of LPA5, allowing us to make cell intrinsic 
comparisons. The results from these experiments revealed that, as predicted, 
LPA5-deficient OT-I CD8+ T cells trended to have a higher proliferative capacity 
and thus a near significant increase in OT-I CD8+ T cell accumulation. We were 
not surprised that the difference in proliferation was not greater between LPA5+/+ 
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and LPA5–/– as in vitro experiments showed that LPA inhibition of activation to 
SIINFEKL was diminished as compared to a lower affinity peptide. In addition, 
the concentration of LPA in plasma is low and has been reported to be ~1µM in 
mouse (150, 168), although we do not know the concentration of LPA in lymph 
nodes or if it is changed by SIINFEKL-BMDC transfer. However in comparison to 
another major lysophospholipid, S1P, it might be expected that the concentration 
of LPA in tissues is reduced relative to blood (190, 191).  
We found that LPA5-deficient OT-I CD8+ T cells were able to proliferate 
and accumulate more robustly than wild type OT-I CD8+ T cells, resulting in few 
cells that had not proliferated and increased accumulation of OT-I CD8+ T cells in 
the draining lymph node. Interestingly, although the LPA5-sufficient OT-I CD8+ T 
cell population had more cells that had not proliferated and were CFSEhigh, the 
cells that had proliferated were able to divide roughly the same number of 
divisions as LPA5–/– OT-I CD8+ T cells. This indicated to us that inhibition via 
LPA5 by endogenous levels of LPA was sufficient to prevent proliferation in a 
subset of the transferred cells and thus remained CFSEhigh. However, the LPA5-
sufficient CD8+ T cells that could be activated despite LPA inhibition via LPA5 
were able to proliferate as efficiently as LPA5-deficient CD8+ T cells. This is 
further evidenced by the similar shape of the proliferation profiles after the first 
division between LPA5+/+ and LPA5–/– OT-I CD8+ T cells (Figure 4.3). This 
suggests that LPA functions to inhibit CD8+ T cell activation at an early event, 
however those cells that are activated despite the presence of LPA, are not 
inhibited from further proliferation. 
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When we examined activation between LPA5+/+ and LPA5–/– OT-I T cells, 
we were surprised to find that LPA5–/– OT-I T cells had lower levels of activation 
marker expression (CD25 and CD44). When we compared CD25 expression with 
proliferation by analyzing CFSE dilution, it appeared that there was a delay in 
CD25 upregulation in LPA5-deficient OT-I CD8+ T cells, such that earlier divisions 
occurred in the absence of CD25 upregulation and only later divisions had 
upregulated CD25. This was in contrast to LPA5-sufficent OT-I CD8+ T cells that 
featured increased CD25 expression with successive divisions. As CD25 is part 
of the IL-2 receptor complex and is upregulated by IL-2 signaling, we questioned 
if LPA5-deficient OT-I CD8+ T cells produced IL-2 differently from LPA5-sufficient 
OT-I CD8+ T cells. Although we did not find a difference in IL-2 production or 
consumption in vitro, we also did not see a difference in CD25 expression as we 
had observed in vivo, therefore we question the relevance of these findings in 
comparison with the in vivo experiments. We therefore decided to further 
characterize the phenotype of responding LPA5-deficient versus LPA5-sufficient 
CD8+ T cells in vivo and look for differences in the kinetics of the response. The 
differences in effector versus memory population generation in response to 
infection have been well characterized and include differences in surface 
markers and cytokine production, including KLRG1 and granzyme B (Figure 5.2). 
Although we know that LPA5-sufficient OT-I T cells are capable of differentiating 
to both memory and effector populations (192), we questioned if the increased 
proliferation we observed with LPA5-deficient OT-I T cells was an indication that a 
lack of LPA5 signaling would skew the differentiation of responding CD8+ T cells 
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Figure 5.2  Does LPA5 signaling influence CD8+ T cell 
differentiation? 
Upon infection, CD8+ T cells that develop into long-term memory T cells 
express KLRG1low and granzyme Blow, whereas terminally differentiated 
effector T cells express KLRG1high and granzyme Bhigh. We question if 
LPA5 signaling could influence the ratio of these outcomes. Figure 
adapted from Belz, 2010 (193). 
 
 
An initial experiment to characterize differences in differentiation was not 
successful, as the effector versus memory phenotype markers analyzed were not 
upregulated in response to SIINFEKL-BMDC activation. This was also 
documented by another group that found that transfer of DC with Listeria 
monocytogenes (Lm) but not DC alone, induced KLRG-1 (194). However we did 
observe an increased population of LPA5–/– OT-I CD8+ T cells relative to LPA5+/+ 
OT-I CD8+ T cells at an earlier timepoint (7 days) and this was reversed at a later 










lack of LPA5 signaling influences CD8+ T cells towards an effector phenotype. 
However as we have shown that LPA5–/– CD8+ T cells exhibit greater proliferation 
in response to stimulation, this may indicate that mutant T cells may also exhibit 
an earlier contraction as the antigen is more rapidly cleared by a larger 
population of specific CD8+ T cells. This could be tracked with an infection model 
by quantifying the infectious burden at different timepoints to determine if the 
infection is cleared more rapidly by LPA5–/– OT-I CD8+ T cells and thus followed 






Figure 5.3  LPA5–/– T cells may have decreased memory 
population formation or an earlier contraction 
A preliminary experiment in which LPA5+/+ or LPA5–/– CD8+ OT-I T cells 
were isolated and 106 CFSE-labeled cells were adoptively transferred 
intravenously to C57BL/6 recipients a day prior to immunization. On day 0, 
106 SIINFEKL-pulsed BMDC were transferred by subcutaneous injection 
to the scruff, similar to Fig. 4.2. On days 7 and 14 after transfer of peptide-
loaded BMDC, mice were sacrificed and the percentage of OT-I of CD8+ T 








































To further investigate the differentiation of LPA5-deficient OT-I CD8+ T 
cells, we examined effector molecule expression, including granzyme B and 
Lamp-1 (CD107a). Lamp-1 is a marker of degranulation and granzyme B causes 
apoptosis in target cells and is produced at high levels in effector T cells but at 
lower levels in memory T cells (Figure 5.2) (159, 193).  When we stimulated 
purified LPA5-deficient OT-I CD8+ T cells in vitro with G4 peptide-pulsed 
splenocytes, we found no difference in Lamp-1 production (data not shown) but a 
higher proportion of LPA5–/– OT-I CD8+ T cells produced granzyme B in response 
to stimulation, as compared to LPA5+/+ OT-I CD8+ T cells (Figure 5.4). As 
granzyme B production by CD8+ T cells causes apoptosis in target cells, 
increased production of granzyme B by LPA5–/– CD8+ T cells in the tumor 
microenviroment may be a factor in the enhanced control of tumor progression 
by LPA5–/– OT-I CD8+ T cells. This higher expression of granzyme B may also 
indicate that LPA5–/– CD8+ T cells differentiate to an effector phenotype, in 
coordination with the results of the memory experiment (Figure 5.3). Future 
studies to pursue this possibility in the context of Lm-OVA peptide infection, as 
earlier described, would allow comparisons of how LPA5 signaling influences 
differentiation of CD8+ T cells to an effector versus memory phenotype in 






Figure 5.4 A higher proportion of LPA5–/– OT-I T cells 
produce granzyme B 
CD8+ T cells were purified from LPA5+/+ (left plot) or LPA5–/– (right plot)  
OT-I splenocytes and lymph nodes, and combined at a 1:2 ratio with 
C57BL/6 splenocytes before pulse with G4 peptide. Cells were washed 
and plated at 2.5 x 106 cells/mL. On day 3, cells were transferred to a 
round-bottom plate and brefeldin A was added for 5 hours. Cells were 
fixed, permeablized, and stained for flow cytometry (n=1). 
 
 
Implications for tumor studies and drug development 
LPA5-deficient T cells more effectively abate tumor progression 
In chapter IV, we also wanted to investigate the role of LPA signaling in 
the CD8+ T cell response to tumor, knowing that various tumors have been 
reported to feature elevated LPA levels (63, 79, 118, 195, 196). Given the 
enhanced proliferation but reduced expression of CD25 and CD44 activation 
markers of LPA5–/– OT-I CD8+ T cells, we were not sure if transfer of LPA5–/– OT-I 
CD8+ T cells would better control tumor growth over LPA5+/+ OT-I CD8+ T cells. 
However we were excited to find that transfer of LPA5-deficient OT-I T cells 
caused abatement of established B16 melanoma growth and significantly smaller 

























tumors. This indicated that even with the increased concentration of LPA 
generated from the tumor, LPA5-deficient tumor-specific T cells were not inhibited 
from controlling tumor growth within an 8-day period. When we extended the 
tumor experiment beyond 8 days as a survival experiment, we found that a single 
transfer of LPA5–/– OT-I T cells was not sufficient to enhance long-term survival 
from tumor challenge. This may suggest that multiple transfers of LPA5-deficient 
OT-I CD8+ T cells may be required to provide long-term protection from tumor. 
Although intracellular IFNγ and TNFα production was similar between LPA5+/+ 
and LPA5–/– CD8+ T cells, LPA5-deficient tumor-specific T cells trended to have 
increased proliferation and accumulation at early timepoints in the tumor, again 
possibly indicating a proliferative advantage and differentiation to an effector 
phenotype. The previous findings that LPA influences chemokinesis in T cells 
(149, 197) fits well with our tumor study findings, as we find increased numbers 
of transferred LPA5-deficient T cells in tumor as compared to LPA5-sufficient T 
cells. Although we found that the presence of LPA alone did not influence naïve 
T cell migration, we did not test the effect of LPA on activated T cell chemotaxis 
and additionally, it has been shown that LPA has a synergistic effect on 
chemotaxis when combined with the chemoattractant, CXCL12 (149). It would be 
useful to identify the LPA receptor responsible for the LPA trafficking phenotype 
and determine if LPA signaling in conjunction with activation affects chemokine 
receptor expression. Given the differential effect of LPA on DC dependent on 
maturation status (133, 134), it would be interesting to compare LPA receptor 
expression and function of naïve versus activated CD8+ T cells, however this 
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would best be analyzed at the protein level by a monoclonal antibody in 
comparison with other surface markers to indicate activation and differentiation 
status, yet flow cytometric antibodies to some LPA receptors (including LPA5) are 
not yet available (104).  
Given our findings, we believe that LPA5-sufficient CD8+ T cells are 
inhibited during activation by cognate peptide, resulting in ablation of proliferation 
in a subset of cells and a resultant decrease in accumulation. It has yet to be 
shown if this inhibition of activation occurs primarily in the tumor 
microenvironment or in the lymph nodes, and whether this occurs with steady 
state levels of LPA or elevated levels of LPA systemically or within the tumor 
microenvironment due to LPA generation by the tumor. Additionally, tumor-
generated LPA may result in altered homing of tumor-specific CD8+ T cells as 
has been shown by other research groups (151, 197, 198), also contributing to a 
reduced concentration of CD8+ T cells within the tumor. Our data suggests that 
this inhibition of activation and possible altered homing results in fewer CD8+ T 
cells in the tumor and reduced anti-tumor adaptive immunity (Figure 5.5A). In 
contrast, when LPA5 signaling is prevented on CD8+ T cells, either by genetic 
ablation as we have shown or as we would predict by blockade of LPA5 via 
receptor-specific antagonists, CD8+ T cells are no longer inhibited to proliferate 
and accumulate (Figure 5.5B). In addition, we have preliminary evidence that a 
higher proportion of LPA5-deficient CD8+ T cells produce granzyme B (Figure 
5.4). This results in an increased intratumoral population of tumor-specific CD8+ 
T cells, with enhanced anti-tumor cytokine production and thus abated tumor 
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progression. We believe that the inhibition of CD8+ T cell activation by LPA 





Figure 5.5 A model: interference with LPA5 signaling 
improves CD8+ T cell anti-tumor immunity 
(A) CD8+ T cells that express LPA5 are inhibited by LPA upon activation, 
resulting in reduced proliferation and accumulation. This reduction in CD8+ 
T cell expansion results in fewer CD8+ T cells in the tumor to exert ant-
tumor effects.  
(B) CD8+ T cells that do not express LPA5 or are treated with LPA5-
blocking treatment accumulate are not inhibited from activation and 
subsequent proliferation. This allows increased expansion and CD8+ T cell 









Considerations for enhancing the CD8+ T cell antitumor response 
Various therapies have been explored to enhance the adaptive immune 
response to tumor, such as enriching and activating tumor-specific T cells ex vivo 
as a T cell therapy, immunizing with a tumor-derived peptide to stimulate tumor-
specific T cells, or enhancing the endogenous T cell response by administration 
of drugs to induce T cell stimulation by activating T cells or antagonizing 
inhibitory receptors (32, 33, 182). Of note, two drugs that are currently in clinical 
trials or have already been approved for use, function by antagonizing inhibitory 
receptors on T cells. These drugs include Yervoy (ipilimumab), which was 
approved by the U.S. Food and Drug Administration in 2011 to treat advanced 
metastatic melanoma and enhances the T cell response by blocking the 
inhibitory receptor, CTLA-4 (199) and BMS-936558, an anti-PD-1 antibody that is 
in Phase I trials to treat various cancers, including melanoma, kidney, and non-
small cell lung cancers (200). The success of these two drugs represents an 
exciting new therapeutic tool to enhance the T cell response to tumor and 
provides compelling evidence that activating T cells in the absence of other 
treatments (chemotherapy, etc.) is sufficient to provide therapeutic antitumoral 
benefits (32). 
G-protein coupled receptors (GPCRs) in particular represent important 
drug targets (201) as over 1% of human genes are postulated to encode GPCRs 
(61) and approximately one third of currently marketed drugs target GPCRs (202, 
203).  A prominent GPCR-targeted drug, FTY720 (GILENYA, fingolimod), targets 
another lysophospholipid, S1P and was approved by the U.S. Food and Drug 
  115 
Association in 2010 to treat relapsing-remitting multiple sclerosis (96). In contrast 
to receptor antagonists, FTY720 acts as an agonist to the GPCR, S1P1,3-5.  
However continued agonism results in functional antagonism, as the S1P 
receptors are internalized and irreversibly degraded (61). This downregulation of 
S1P1, in particular, results in sequestration of lymphocytes in lymph nodes, 
thereby preventing their contribution to autoimmunity. FTY720 is also being 
tested in type I diabetes, systemic lupus erythematosus, rheumatoid arthritis, and 
other autoimmune diseases, and FTY720-related agonists are also being 
developed to more selectively target S1P1. The concept of receptor agonism to 
induce functional antagonism could be explored to reduce LPA5 signaling, as 
LPA5 is also internalized upon ligand binding (108), although it is not yet clear if it 
is subsequently irreversibly degraded.   
LPA receptor-targeted drugs have been developed, however these 
compounds tend to lack in vivo validation and receptor selectivity (61). VPC-
12449 is a LPA1,3 antagonist and has been shown to protect against renal 
ischemia-reperfusion injury via LPA3 in mice (204). Ki16425 is a also a LPA1,3 
antagonist that has been shown to inhibit breast cancer cell proliferation and 
metastasis in mice (205). BrP-LPA is an LPA analog that antagonizes LPA1-4, 
inhibits ATX function, and has been shown to inhibit blood vessel density and 
tumor size in a mouse breast cancer model (206) and non-small cell lung cancer 
(NSCLC) (207). Although BrP-LPA was designed to target cancer cells, this 
compound antagonizes LPA2, which we have found to be expressed on T and B 
cells (Figure 3.4)(152). Thus it would be important to understand the impact of 
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LPA2 and other LPA receptor antagonism on immune cells. To the author’s 
knowledge, an LPA5-specific antagonist has not been developed although it 
would be interesting to test the effects of such a compound in a tumor model. 
Given that we know that LPA has been shown to be beneficial to the tumor, an 
LPA-depleting treatment would theoretically be detrimental to the tumor while 
simultaneously enhancing the CD8+ T cell response. Anti-cancer therapies that 
function to reduce LPA concentration by inhibiting ATX function are being 
developed (67, 73, 75, 208-210). The side effects of such a treatment have yet to 
be reported, however detrimental complications could prevent long-term use of 
ATX inhibitors, as LPA is important for vascular development and osteogenesis 
(71, 211). 
 Success with metastatic melanoma has resulted in 47 new clinical trials to 
test the efficacy of Yervoy against other cancers, such as prostate cancer, non-
small cell lung cancer, and even graft versus host disease (212). Although 
Yervoy has been widely celebrated as a breakthrough in cancer immunotherapy, 
this treatment has caveats. It is not surprising that global blockade of a T cell 
inhibitory receptor has resulted in reports of increased autoimmunity, such as 
autoimmune hypophysitis (212) and colitis (32). Given the lymphoproliferative 
disease observed in CTLA-4–/– mice as we described earlier in this chapter, it 
follows that blockade of this receptor causes normally quiescent T cells to 
respond in the absence of infection or other stimulation. We have not seen 
lymphoproliferative disease in LPA5–/– mice and given that we have shown 
inhibition is only in conjunction with TCR stimulation, we propose that blocking 
  117 
LPA5 signaling to enhance the T cell response could represent a preferable 
approach to cancer immunotherapy. We have found that ablation of LPA5 
signaling only enhances the response of T cells upon activation, leaving 
unactivated and possibly autoreactive cells unresponsive to LPA5 blockade. 
Although this may exclude the possibility of stimulating unactivated tumor-
specific T cells into action, this may avoid autoimmune complications 
experienced by roughly a quarter of Yervoy patients (32).  
 In addition, it is important to consider combination therapies when 
developing cancer immunotherapies. It is known that cancer patients have tumor-
specific T cells that can be elicited to respond to the tumor by determination of 
immunogenic tumor-derived peptides and immunizing patients with those 
peptides (32). Additionally, approaches to enhance stimulation of T cells 
indirectly by increased APC function have been attempted (32). DC-based 
vaccines have been tested in the clinic to induce T cell responses to tumor by 
transfer of antigen-loaded DC, though the results have not been impressive (213). 
Further efficiency of targeting to CD8+ T cells has been achieved by targeting 
CD8+ DC in vivo, which are specialized in cross presentation of antigens in MHC 
class I (214). By this method, others have successfully bolstered CD8+ T cell 
activation by conjugating the immunizing peptide to antibodies to target CD8+ DC, 
in combination with a DC agonist to induce maturation (215, 216). This approach 
has been examined to enhance the CD8+ T cell response to HIV (216-218), as 
well as some cancers (219). This approach may be further strengthened in 
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combination with a blocking LPA5 treatment, to enhance presentation of tumor 
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